<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns:dt="uuid:C2F41010-65B3-11d1-A29F-00AA00C14882"
xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 9">
<meta name=Originator content="Microsoft Word 9">
<link rel=File-List
href="./4017B1-06c%20Thalomid%20PI%20Section%20C%20Tab%208_files/filelist.xml">
<link rel=Edit-Time-Data
href="./4017B1-06c%20Thalomid%20PI%20Section%20C%20Tab%208_files/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title>“DRAFT / PROPOSED PRESCRIBING INFORMATION”</title>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>wwoolever</o:Author>
  <o:LastAuthor>OC</o:LastAuthor>
  <o:Revision>2</o:Revision>
  <o:TotalTime>2</o:TotalTime>
  <o:LastPrinted>2004-01-29T17:22:00Z</o:LastPrinted>
  <o:Created>2004-02-14T00:39:00Z</o:Created>
  <o:LastSaved>2004-02-14T00:39:00Z</o:LastSaved>
  <o:Pages>16</o:Pages>
  <o:Words>8716</o:Words>
  <o:Characters>49686</o:Characters>
  <o:Company>Dell Computer Corporation</o:Company>
  <o:Lines>414</o:Lines>
  <o:Paragraphs>99</o:Paragraphs>
  <o:CharactersWithSpaces>61017</o:CharactersWithSpaces>
  <o:Version>9.3821</o:Version>
 </o:DocumentProperties>
 <o:CustomDocumentProperties>
  <o:_AdHocReviewCycleID dt:dt="float">482581992</o:_AdHocReviewCycleID>
  <o:_EmailSubject dt:dt="string">STEPS info available to send out to advisory committee on 1/29??</o:_EmailSubject>
  <o:_AuthorEmail dt:dt="string">COXE@cder.fda.gov</o:_AuthorEmail>
  <o:_AuthorEmailDisplayName dt:dt="string">Cox, Edward M</o:_AuthorEmailDisplayName>
  <o:_PreviousAdHocReviewCycleID dt:dt="float">1662805600</o:_PreviousAdHocReviewCycleID>
  <o:_ReviewingToolsShownOnce dt:dt="string"></o:_ReviewingToolsShownOnce>
 </o:CustomDocumentProperties>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:DoNotShowRevisions/>
  <w:DoNotPrintRevisions/>
  <w:Compatibility>
   <w:FootnoteLayoutLikeWW8/>
   <w:ShapeLayoutLikeWW8/>
   <w:AlignTablesRowByRow/>
   <w:ForgetLastTabAlignment/>
   <w:LayoutRawTableWidth/>
   <w:LayoutTableRowsApart/>
  </w:Compatibility>
 </w:WordDocument>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:536902279 -2147483648 8 0 511 0;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1 -369098753 63 0 4129023 0;}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;
	mso-font-charset:128;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-1 -369098753 63 0 4129023 0;}
 /* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin:0pt;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
h1
	{mso-style-next:Normal;
	margin:0pt;
	margin-bottom:.0001pt;
	text-align:center;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	mso-layout-grid-align:none;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Arial Unicode MS";
	mso-font-kerning:0pt;
	mso-bidi-font-weight:normal;}
h2
	{mso-style-next:Normal;
	margin:0pt;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:2;
	mso-layout-grid-align:none;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:12.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Arial Unicode MS";
	mso-bidi-font-weight:normal;}
h3
	{mso-style-next:Normal;
	margin:0pt;
	margin-bottom:.0001pt;
	text-align:center;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:3;
	mso-layout-grid-align:none;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:9.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Arial Unicode MS";
	mso-bidi-font-weight:normal;}
h4
	{mso-style-next:Normal;
	margin:0pt;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:4;
	mso-layout-grid-align:none;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Arial Unicode MS";
	mso-bidi-font-weight:normal;}
h5
	{mso-style-next:Normal;
	margin:0pt;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:5;
	mso-layout-grid-align:none;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Arial Unicode MS";
	mso-bidi-font-weight:normal;}
h6
	{mso-style-next:Normal;
	margin-top:0pt;
	margin-right:0pt;
	margin-bottom:0pt;
	margin-left:-4.5pt;
	margin-bottom:.0001pt;
	text-indent:22.5pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:6;
	mso-layout-grid-align:none;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Arial Unicode MS";
	mso-bidi-font-weight:normal;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-next:Normal;
	margin:0pt;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:7;
	mso-layout-grid-align:none;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:Times;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	color:blue;
	font-weight:bold;
	mso-bidi-font-weight:normal;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-next:Normal;
	margin:0pt;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:8;
	mso-list:skip;
	font-size:8.0pt;
	mso-bidi-font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;
	mso-bidi-font-weight:normal;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0pt;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	tab-stops:center 216.0pt right 432.0pt;
	mso-layout-grid-align:none;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:12.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{margin:0pt;
	margin-bottom:.0001pt;
	text-align:center;
	mso-pagination:widow-orphan;
	mso-layout-grid-align:none;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:12.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	color:red;
	font-weight:bold;
	mso-bidi-font-weight:normal;
	font-style:italic;
	mso-bidi-font-style:normal;
	text-decoration:underline;
	text-underline:single;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin:0pt;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	mso-layout-grid-align:none;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:12.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{margin:0pt;
	margin-bottom:.0001pt;
	text-align:center;
	mso-pagination:widow-orphan;
	mso-outline-level:1;
	font-size:11.0pt;
	mso-bidi-font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin:0pt;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	mso-layout-grid-align:none;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:11.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:Times;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{margin:0pt;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	mso-layout-grid-align:none;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:12.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	font-weight:bold;
	mso-bidi-font-weight:normal;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{margin:0pt;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	mso-layout-grid-align:none;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:10.0pt;
	font-family:"Courier New";
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
@page Section1
	{size:612.0pt 792.0pt;
	margin:28.8pt 36.0pt 28.8pt 43.2pt;
	mso-header-margin:36.0pt;
	mso-footer-margin:36.0pt;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
@page Section2
	{size:612.0pt 792.0pt;
	margin:43.2pt 50.4pt 50.4pt 50.4pt;
	mso-header-margin:36.0pt;
	mso-footer-margin:36.0pt;
	mso-paper-source:0;}
div.Section2
	{page:Section2;}
 /* List Definitions */
@list l0
	{mso-list-id:-2;
	mso-list-type:simple;
	mso-list-template-ids:2132209432;}
@list l0:level1
	{mso-level-start-at:0;
	mso-level-text:*;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	margin-left:0pt;
	text-indent:0pt;}
@list l1
	{mso-list-id:48462481;
	mso-list-type:simple;
	mso-list-template-ids:-1685186112;}
@list l1:level1
	{mso-level-start-at:8;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:30.0pt;
	mso-level-legacy-space:6.0pt;
	text-indent:-30.0pt;}
@list l0:level1 lfo2
	{mso-level-number-format:bullet;
	mso-level-numbering:continue;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:18.0pt;
	mso-level-legacy-space:6.0pt;
	margin-left:18.0pt;
	text-indent:-18.0pt;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l0:level1 lfo3
	{mso-level-number-format:bullet;
	mso-level-numbering:continue;
	mso-level-text:\F0B7;
	mso-level-tab-stop:none;
	mso-level-number-position:left;
	mso-level-legacy:yes;
	mso-level-legacy-indent:18.0pt;
	mso-level-legacy-space:6.0pt;
	margin-left:18.0pt;
	text-indent:-18.0pt;
	mso-ansi-font-size:9.0pt;
	font-family:Symbol;}
ol
	{margin-bottom:0pt;}
ul
	{margin-bottom:0pt;}
-->
</style>
<!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="2050"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=EN-US style='tab-interval:36.0pt'>

<div class=Section1>

<p class=MsoTitle align=left style='text-align:left;mso-outline-level:1'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;color:black'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoSubtitle>THALOMID® (thalidomide) Capsules 50 mg, 100 mg, &amp;
200mg</p>

<p class=MsoNormal align=center style='text-align:center'><span
style='font-size:11.0pt;mso-bidi-font-size:12.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<div align=center>

<table border=0 cellspacing=0 cellpadding=0 style='border-collapse:collapse;
 mso-padding-alt:0pt 4.8pt 0pt 4.8pt'>
 <tr style='height:20.1pt'>
  <td width=624 valign=top style='width:468.0pt;border:solid windowtext .75pt;
  padding:0pt 4.8pt 0pt 4.8pt;height:20.1pt'>
  <h2><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt'>WARNING: SEVERE,
  LIFE-THREATENING HUMAN BIRTH DEFECTS.<o:p></o:p></span></h2>
  <p class=MsoBodyText3 style='margin-top:4.0pt;mso-pagination:widow-orphan no-line-numbers'><span
  style='font-size:11.0pt;mso-bidi-font-size:10.0pt'>IF THALIDOMIDE IS TAKEN
  DURING PREGNANCY, IT CAN CAUSE SEVERE BIRTH DEFECTS OR DEATH TO AN UNBORN
  BABY. THALIDOMIDE SHOULD NEVER BE USED BY WOMEN WHO ARE PREGNANT OR WHO COULD
  BECOME PREGNANT WHILE TAKING THE DRUG. EVEN A SINGLE DOSE [1 CAPSULE (50 mg,
  100 mg or 200<span style='color:red'> </span>mg)] TAKEN BY A PREGNANT WOMAN
  DURING HER PREGNANCY CAN CAUSE SEVERE BIRTH DEFECTS.<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;mso-pagination:widow-orphan no-line-numbers'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>BECAUSE OF THIS TOXICITY AND IN AN EFFORT TO MAKE THE CHANCE OF FETAL
  EXPOSURE TO THALOMID<sup>®</sup> (thalidomide) AS NEGLIGIBLE AS POSSIBLE,
  THALOMID<sup>®</sup> (thalidomide) IS APPROVED FOR MARKETING ONLY UNDER A
  SPECIAL RESTRICTED DISTRIBUTION PROGRAM APPROVED BY THE FOOD AND DRUG
  ADMINISTRATION. THIS PROGRAM IS CALLED THE &quot;SYSTEM FOR THALIDOMIDE
  EDUCATION AND PRESCRIBING SAFETY (<i style='mso-bidi-font-style:normal'>S.T.E.P.S.</i><sup><span
  style='color:red'> </span>®</sup>).&quot;<span style="mso-spacerun: yes"> 
  </span><o:p></o:p></span></b></p>
  <p class=MsoNormal style='margin-top:2.0pt;mso-pagination:widow-orphan no-line-numbers'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>UNDER THIS RESTRICTED DISTRIBUTION PROGRAM, ONLY PRESCRIBERS AND
  PHARMACISTS REGISTERED WITH THE PROGRAM ARE ALLOWED TO PRESCRIBE AND DISPENSE
  THE PRODUCT. IN ADDITION, PATIENTS MUST BE ADVISED OF, AGREE TO, AND COMPLY
  WITH THE REQUIREMENTS OF THE <i style='mso-bidi-font-style:normal'>S.T.E.P.S.</i><sup><span
  style='color:red'> </span>®</sup> PROGRAM IN ORDER TO RECEIVE PRODUCT.<span
  style="mso-spacerun: yes">  </span><o:p></o:p></span></b></p>
  <p class=MsoNormal style='margin-top:2.0pt;mso-pagination:widow-orphan no-line-numbers'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>PLEASE SEE THE FOLLOWING BOXED WARNINGS CONTAINING SPECIAL
  INFORMATION FOR PRESCRIBERS, FEMALE PATIENTS, AND MALE PATIENTS ABOUT THIS
  RESTRICTED DISTRIBUTION PROGRAM.<u><o:p></o:p></u></span></b></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal align=center style='margin-left:18.0pt;text-align:center;
mso-pagination:widow-orphan no-line-numbers;tab-stops:center 216.0pt right 450.0pt'><b
style='mso-bidi-font-weight:normal'><u><span style='font-size:11.0pt;
mso-bidi-font-size:12.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></u></b></p>

<div align=center>

<table border=1 cellspacing=0 cellpadding=0 style='border-collapse:collapse;
 border:none;mso-border-alt:solid windowtext .5pt;mso-padding-alt:0pt 4.8pt 0pt 4.8pt'>
 <tr style='height:20.1pt'>
  <td width=624 valign=top style='width:468.0pt;border-top:none;border-left:
  solid windowtext .5pt;border-bottom:none;border-right:solid windowtext .5pt;
  padding:0pt 4.8pt 0pt 4.8pt;height:20.1pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-pagination:widow-orphan no-line-numbers'><!--[if gte vml 1]><v:line
   id="_x0000_s1028" style='position:absolute;left:0;text-align:left;z-index:2;
   mso-wrap-edited:f' from="8.45pt,1.55pt" to="476.45pt,1.55pt" wrapcoords="-35 0 -35 0 21669 0 21669 0 -35 0"
   o:allowincell="f">
   <w:wrap type="tight"/>
  </v:line><![endif]--><![if !vml]><img width=627 height=3
  src="./4017B1-06c%20Thalomid%20PI%20Section%20C%20Tab%208_files/image001.gif"
  align=left hspace=12 v:shapes="_x0000_s1028"><![endif]><b style='mso-bidi-font-weight:
  normal'><u><span style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>PRESCRIBERS<o:p></o:p></span></u></b></p>
  <p class=MsoNormal style='margin-top:4.0pt;mso-pagination:widow-orphan no-line-numbers'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>THALOMID<sup>®</sup>
  (thalidomide) may be prescribed only by licensed prescribers who are
  registered in the <i style='mso-bidi-font-style:normal'>S.T.E.P.S.</i><b
  style='mso-bidi-font-weight:normal'><sup><span style='color:red'> </span>®</sup></b>
  program and understand the risk of teratogenicity if thalidomide is used
  during pregnancy.<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:4.0pt;mso-pagination:widow-orphan no-line-numbers'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>Major human fetal
  abnormalities related to thalidomide administration during pregnancy have
  been documented:<span style="mso-spacerun: yes">  </span>amelia (absence of
  limbs), phocomelia (short limbs), hypoplasticity of the bones, absence of
  bones, external ear abnormalities (including anotia, micro pinna, small or
  absent external auditory canals), facial palsy, eye abnormalities
  (anophthalmos, microphthalmos), and congenital heart defects. Alimentary
  tract, urinary tract, and genital malformations have also been documented.<sup>1</sup>
  Mortality at or shortly after birth has been reported at about 40%.<sup>2<o:p></o:p></sup></span></p>
  <p class=MsoNormal style='margin-top:4.0pt;mso-pagination:widow-orphan no-line-numbers'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>Effective contraception
  (see <b style='mso-bidi-font-weight:normal'>CONTRAINDICATIONS</b>) must be
  used <span style='color:black'>for at least 4 weeks before beginning
  thalidomide therapy, during thalidomide therapy, and for 4 weeks following
  discontinuation of thalidomide therapy. Reliable contraception is indicated
  even where</span> there has been a history of infertility, unless due to
  hysterectomy or because the patient has been postmenopausal for at least 24
  months. Two reliable forms of contraception must be used simultaneously unless
  continuous abstinence from heterosexual sexual contact is the chosen method.
  Women of childbearing potential should be referred to a qualified provider of
  contraceptive methods, if needed. Sexually mature women who have not
  undergone a hysterectomy or who have not been postmenopausal for at least 24
  consecutive months (i.e., who have had menses at some time in the preceding
  24 consecutive months) are considered to be women of childbearing potential.<b
  style='mso-bidi-font-weight:normal'><o:p></o:p></b></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;mso-pagination:widow-orphan no-line-numbers'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>Before starting treatment</span></b><span style='font-size:11.0pt;
  mso-bidi-font-size:12.0pt'>, women of childbearing potential should have a
  pregnancy test (sensitivity of at least 50 mIU/mL). The test should be
  performed within the 24 hours prior to beginning thalidomide therapy.<span
  style="mso-spacerun: yes">  </span>A prescription for thalidomide for a woman
  of childbearing potential must not be issued by the prescriber until a
  written report of a negative pregnancy test has been obtained by the
  prescriber.<span style='color:red'><o:p></o:p></span></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;mso-pagination:widow-orphan no-line-numbers'><i
  style='mso-bidi-font-style:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>Male Patients</span></i><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>: Because thalidomide is present in the semen of patients receiving
  the drug, males receiving thalidomide must always use a latex condom during
  any sexual contact with women of childbearing potential even if he has
  undergone a successful vasectomy.<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;mso-pagination:widow-orphan no-line-numbers'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>Once treatment has started</span></b><span style='font-size:11.0pt;
  mso-bidi-font-size:12.0pt'>, pregnancy testing should occur weekly during the
  first 4 weeks of use, then pregnancy testing should be repeated at 4 weeks in
  women with regular menstrual cycles. If menstrual cycles are irregular, the
  pregnancy testing should occur every 2 weeks. Pregnancy testing and
  counseling should be performed if a patient misses her period or if there is
  any abnormality in menstrual bleeding.<o:p></o:p></span></p>
  <p class=MsoBodyText style='margin-top:4.0pt;mso-pagination:widow-orphan no-line-numbers'><span
  style='font-size:11.0pt;mso-bidi-font-size:10.0pt'>If pregnancy does occur
  during thalidomide treatment, thalidomide must be discontinued immediately. <o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:4.0pt'><span style='font-size:11.0pt;
  mso-bidi-font-size:12.0pt'>Any suspected fetal exposure to THALOMID<b
  style='mso-bidi-font-weight:normal'><sup>®</sup></b> (thalidomide) must be
  reported immediately to the FDA <i style='mso-bidi-font-style:normal'>via</i>
  the MedWatch<span style='color:red'> </span>number at 1-800-FDA-1088 and also
  to Celgene Corporation. The patient should be referred to an
  obstetrician/gynecologist experienced in reproductive toxicity for further
  evaluation and counseling.<b style='mso-bidi-font-weight:normal'><u><o:p></o:p></u></b></span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoPlainText><!--[if gte vml 1]><v:line id="_x0000_s1029" style='position:absolute;
 flip:y;z-index:3;mso-wrap-edited:f;mso-position-horizontal:left;
 mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
 from="0,2.45pt" to="468.65pt,2.9pt" wrapcoords="-35 0 -35 0 21669 0 21669 0 -35 0"
 o:allowincell="f">
 <w:wrap type="square"/>
</v:line><![endif]--><![if !vml]><img width=628 height=4
src="./4017B1-06c%20Thalomid%20PI%20Section%20C%20Tab%208_files/image002.gif"
align=left hspace=12 v:shapes="_x0000_s1029"><![endif]><!--[if gte vml 1]><v:line
 id="_x0000_s1026" style='position:absolute;z-index:1;mso-wrap-edited:f;
 mso-position-horizontal:left;mso-position-horizontal-relative:text;
 mso-position-vertical-relative:text' from="0,2.45pt" to="0,2.45pt"
 wrapcoords="0 0 0 0 0 0 0 0 0 0" o:allowincell="f">
 <w:wrap type="square"/>
</v:line><![endif]--><![if !vml]><img width=3 height=3
src="./4017B1-06c%20Thalomid%20PI%20Section%20C%20Tab%208_files/image003.gif"
align=left hspace=12 v:shapes="_x0000_s1026"><![endif]><span style='font-size:
11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><span
style="mso-spacerun:
yes">                                                             </span><b
style='mso-bidi-font-weight:normal'><u><o:p></o:p></u></b></span></p>

<div align=center>

<table border=0 cellspacing=0 cellpadding=0 style='border-collapse:collapse;
 mso-padding-alt:0pt 4.8pt 0pt 4.8pt'>
 <tr style='height:20.1pt'>
  <td width=624 valign=top style='width:468.0pt;border:solid windowtext .75pt;
  border-bottom:none;padding:0pt 4.8pt 0pt 4.8pt;height:20.1pt'>
  <p class=MsoNormal align=center style='text-align:center'><b
  style='mso-bidi-font-weight:normal'><u><span style='font-size:11.0pt;
  mso-bidi-font-size:12.0pt'>FEMALE PATIENTS</span></u></b><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:20.1pt'>
  <td width=624 valign=top style='width:468.0pt;border-top:none;border-left:
  solid windowtext .75pt;border-bottom:solid windowtext .5pt;border-right:solid windowtext .75pt;
  padding:0pt 4.8pt 0pt 4.8pt;height:20.1pt'>
  <p class=MsoNormal><span style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>Thalidomide
  is contraindicated in WOMEN of childbearing potential unless alternative
  therapies are considered inappropriate AND the patient MEETS ALL OF THE
  FOLLOWING CONDITIONS (i.e., she is essentially unable to become pregnant
  while on thalidomide therapy):<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:2.0pt;margin-right:0pt;margin-bottom:
  0pt;margin-left:18.0pt;margin-bottom:.0001pt;text-indent:-18.0pt;mso-list:
  l0 level1 lfo2;tab-stops:18.0pt 36.0pt'><![if !supportLists]><span
  style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>she understands and can reliably carry out instructions.<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0pt;margin-right:0pt;margin-bottom:2.0pt;
  margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo2;tab-stops:
  18.0pt 36.0pt'><![if !supportLists]><span style='font-size:10.0pt;mso-bidi-font-size:
  12.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>she is capable of complying with the mandatory contraceptive
  measures, pregnancy testing, patient registration, and patient survey as
  described in the System for Thalidomide Education and Prescribing Safety (<i
  style='mso-bidi-font-style:normal'>S.T.E.P.S.</i><b style='mso-bidi-font-weight:
  normal'><sup><span style='color:red'> </span>®</sup></b>) program.<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0pt;margin-right:0pt;margin-bottom:2.0pt;
  margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo2;tab-stops:
  18.0pt 36.0pt'><![if !supportLists]><span style='font-size:10.0pt;mso-bidi-font-size:
  12.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>she has received both oral and written warnings of the hazards of
  taking thalidomide during pregnancy and of exposing a fetus to the drug.<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0pt;margin-right:0pt;margin-bottom:2.0pt;
  margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo2;tab-stops:
  18.0pt 36.0pt'><![if !supportLists]><span style='font-size:10.0pt;mso-bidi-font-size:
  12.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>she has received both oral and written warnings of the risk of
  possible contraception failure and of the need to use two reliable forms of
  contraception simultaneously <i style='mso-bidi-font-style:normal'>(</i>see <b
  style='mso-bidi-font-weight:normal'>CONTRAINDICATIONS</b>), unless continuous
  abstinence from heterosexual sexual contact is the chosen method. Sexually
  mature women who have not undergone a hysterectomy or who have not been
  postmenopausal for at least 24 consecutive months (i.e., who have had menses
  at some time in the preceding 24 consecutive months) are considered to be
  women of childbearing potential.<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0pt;margin-right:0pt;margin-bottom:2.0pt;
  margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo2;tab-stops:
  18.0pt 36.0pt'><![if !supportLists]><span style='font-size:10.0pt;mso-bidi-font-size:
  12.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>she acknowledges, in writing, her understanding of these warnings and
  of the need for using two reliable methods of contraception for 4 weeks prior
  to beginning<span style='color:red'> </span>thalidomide therapy, during
  thalidomide therapy, and for 4 weeks after discontinuation of thalidomide
  therapy.<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0pt;margin-right:0pt;margin-bottom:2.0pt;
  margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo2;tab-stops:
  18.0pt 36.0pt'><![if !supportLists]><span style='font-size:10.0pt;mso-bidi-font-size:
  12.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>she has had a negative pregnancy test with a sensitivity of at least
  50 mIU/mL, within the 24 hours prior to beginning therapy. (See <b
  style='mso-bidi-font-weight:normal'>PRECAUTIONS, CONTRAINDICATIONS</b>.)<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0pt;margin-right:0pt;margin-bottom:3.0pt;
  margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo2;tab-stops:
  18.0pt 36.0pt'><![if !supportLists]><span style='font-size:10.0pt;mso-bidi-font-size:
  12.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>if the patient is between 12 and 18 years of age, her parent or legal
  guardian must have read this material and agreed to ensure compliance with
  the above.<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:20.1pt'>
  <td width=624 valign=top style='width:468.0pt;border-top:none;border-left:
  solid windowtext .5pt;border-bottom:none;border-right:solid windowtext .5pt;
  mso-border-top-alt:solid windowtext .5pt;padding:0pt 4.8pt 0pt 4.8pt;
  height:20.1pt'>
  <p class=MsoNormal align=center style='text-align:center'><b
  style='mso-bidi-font-weight:normal'><u><span style='font-size:11.0pt;
  mso-bidi-font-size:12.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></u></b></p>
  <p class=MsoNormal><b style='mso-bidi-font-weight:normal'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'><span style="mso-spacerun:
  yes">                                                            </span><u>MALE
  PATIENTS<o:p></o:p></u></span></b></p>
  <p class=MsoNormal><![if !supportEmptyParas]>&nbsp;<![endif]><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:20.1pt'>
  <td width=624 valign=top style='width:468.0pt;border:solid windowtext .5pt;
  border-top:none;padding:0pt 4.8pt 0pt 4.8pt;height:20.1pt'>
  <p class=MsoNormal style='mso-list:skip'><span style='font-size:11.0pt;
  mso-bidi-font-size:12.0pt'>Thalidomide is contraindicated in sexually mature
  MALES unless the PATIENT MEETS ALL OF THE FOLLOWING CONDITIONS:<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:0pt;margin-bottom:
  2.0pt;margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo2;
  tab-stops:18.0pt 36.0pt'><![if !supportLists]><span style='font-size:10.0pt;
  mso-bidi-font-size:12.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>he understands and can reliably carry out instructions.<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0pt;margin-right:0pt;margin-bottom:2.0pt;
  margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo2;tab-stops:
  18.0pt 36.0pt'><![if !supportLists]><span style='font-size:10.0pt;mso-bidi-font-size:
  12.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>he is capable of complying with the mandatory contraceptive measures
  that are appropriate for men, patient registration, and patient survey as
  described in the <i style='mso-bidi-font-style:normal'>S.T.E.P.S.</i><b
  style='mso-bidi-font-weight:normal'><sup><span style='color:red'> </span>®</sup></b>
  program.<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0pt;margin-right:0pt;margin-bottom:2.0pt;
  margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo2;tab-stops:
  18.0pt 36.0pt'><![if !supportLists]><span style='font-size:10.0pt;mso-bidi-font-size:
  12.0pt;font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>he has received both oral and written warnings of the hazards of
  taking thalidomide and <span style='color:black'>exposing a fetus to the
  drug.<o:p></o:p></span></span></p>
  <p class=MsoNormal style='margin-top:0pt;margin-right:0pt;margin-bottom:2.0pt;
  margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo2;tab-stops:
  18.0pt 36.0pt'><![if !supportLists]><span style='font-size:10.0pt;mso-bidi-font-size:
  12.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt;color:black'>he has received both oral and written warnings of the
  risk of possible contraception failure and of the presence of thalidomide in
  semen. He has been instructed that he must always use </span><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>a<span style='color:black'>
  latex condom during any sexual contact with women of childbearing potential,
  even if he has undergone </span>a <span style='color:black'>successful
  vasectomy.</span><o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0pt;margin-right:0pt;margin-bottom:2.0pt;
  margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo2;tab-stops:
  18.0pt 36.0pt'><![if !supportLists]><span style='font-size:10.0pt;mso-bidi-font-size:
  12.0pt;font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>he acknowledges, in writing, his understanding of these warnings and
  of the need to use a latex condom during any sexual contact with women of <span
  style='color:red'><span style="mso-spacerun: yes"> </span></span>childbearing
  potential, even if he has undergone a successful vasectomy. Sexually mature
  women who have not undergone a hysterectomy or who have not been
  postmenopausal for at least 24 consecutive months (i.e., who have had menses
  at any time in the preceding 24 consecutive months) are considered to be
  women of childbearing potential.<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-left:18.0pt;text-indent:-18.0pt;mso-list:
  l0 level1 lfo2;tab-stops:18.0pt 36.0pt'><![if !supportLists]><span
  style='font-size:10.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>if the patient is between 12 and 18 years of age, his parent or legal
  guardian must have read this material and agreed to ensure compliance with
  the above.<o:p></o:p></span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoPlainText style='mso-outline-level:1;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></b></p>

<p class=MsoPlainText style='mso-outline-level:1;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></b></p>

<p class=MsoPlainText style='mso-outline-level:1;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'>DESCRIPTION</span></b><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><o:p></o:p></span></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>THALOMID<sup>®</sup>
(thalidomide), </span><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;
font-family:Symbol;mso-ascii-font-family:"Times New Roman";mso-hansi-font-family:
"Times New Roman";mso-char-type:symbol;mso-symbol-font-family:Symbol'><span
style='mso-char-type:symbol;mso-symbol-font-family:Symbol'>a</span></span><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>-(N-phthalimido)glutarimide,
is an immunomodulatory agent. The empirical formula for thalidomide is C<sub>13</sub>H<sub>10</sub>N<sub>2</sub>O<sub>4</sub>
and the gram molecular weight is 258.2. The CAS number of thalidomide is
50-35-1.<o:p></o:p></span></p>

<p class=MsoPlainText align=center style='margin-top:2.0pt;text-align:center;
mso-outline-level:1;mso-list:skip'><b style='mso-bidi-font-weight:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Chemical
Structure of thalidomide</span></b><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'><span style="mso-spacerun: yes">  
</span><span style="mso-spacerun: yes">      </span><b style='mso-bidi-font-weight:
normal'><s><o:p></o:p></s></b></span></p>

<div style='mso-element:frame;mso-element-frame-width:274.5pt;mso-element-frame-height:
144.0pt;mso-element-frame-hspace:12.0pt;mso-element-frame-vspace:12.0pt;
mso-element-wrap:auto;mso-element-anchor-vertical:paragraph;mso-element-anchor-horizontal:
page;mso-element-left:175.1pt;mso-element-top:14.05pt'>

<table cellspacing=0 cellpadding=0 hspace=0 vspace=0 width=382 height=224>
 <tr>
  <td valign=top align=left height=224 style='padding-top:12.0pt;padding-right:
  12.0pt;padding-bottom:12.0pt;padding-left:12.0pt'>
  <p class=MsoNormal align=right style='text-align:right;mso-list:skip;
  tab-stops:center 216.0pt right 450.0pt;mso-element:frame;mso-element-frame-width:
  274.5pt;mso-element-frame-height:144.0pt;mso-element-frame-hspace:12.0pt;
  mso-element-frame-vspace:12.0pt;mso-element-wrap:auto;mso-element-anchor-vertical:
  paragraph;mso-element-anchor-horizontal:page;mso-element-left:175.1pt;
  mso-element-top:14.05pt'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
   o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
   stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:275.25pt;
   height:2in' fillcolor="window">
   <v:imagedata src="./4017B1-06c%20Thalomid%20PI%20Section%20C%20Tab%208_files/image004.wmz"
    o:title=""/>
  </v:shape><![endif]--><![if !vml]><img width=367 height=192
  src="./4017B1-06c%20Thalomid%20PI%20Section%20C%20Tab%208_files/image005.gif"
  v:shapes="_x0000_i1025"><![endif]><o:p></o:p></span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoPlainText align=center style='text-align:center;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></b></p>

<p class=MsoNormal align=right style='text-align:right;mso-list:skip;
tab-stops:center 216.0pt right 450.0pt'><span style='font-size:11.0pt;
mso-bidi-font-size:12.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoPlainText align=center style='text-align:center;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><span
style='mso-tab-count:5'>                                                            </span><o:p></o:p></span></p>

<p class=MsoPlainText align=center style='text-align:center;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoPlainText align=center style='text-align:center;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoPlainText align=center style='text-align:center;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoPlainText align=center style='text-align:center;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoPlainText align=center style='margin-left:144.0pt;text-align:center;
text-indent:36.0pt;mso-list:skip'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoPlainText align=center style='margin-left:144.0pt;text-align:center;
text-indent:36.0pt;mso-list:skip'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoPlainText align=center style='margin-left:144.0pt;text-align:center;
text-indent:36.0pt;mso-list:skip'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoPlainText align=center style='margin-left:144.0pt;text-align:center;
text-indent:36.0pt;mso-outline-level:1;mso-list:skip'><span style='font-size:
11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><span
style="mso-spacerun: yes">         </span><o:p></o:p></span></p>

<p class=MsoPlainText style='margin-left:144.0pt;text-indent:36.0pt;mso-outline-level:
1;mso-list:skip'><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;
font-family:"Times New Roman"'><span style="mso-spacerun: yes">         </span><o:p></o:p></span></p>

<p class=MsoPlainText align=right style='text-align:right;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman";color:red'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><span
style="mso-spacerun:
yes">                                                                                                                                 
</span>Note: </span><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;
font-family:Symbol;mso-ascii-font-family:"Times New Roman";mso-hansi-font-family:
"Times New Roman";mso-char-type:symbol;mso-symbol-font-family:Symbol'><span
style='mso-char-type:symbol;mso-symbol-font-family:Symbol'>·</span></span><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>
= asymmetric carbon atom<span style="mso-spacerun:
yes">                                                </span><span
style="mso-spacerun: yes">     </span><o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:12.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Thalidomide
is an off-white to white, odorless, crystalline powder that is soluble at 25</span><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:Symbol;
mso-ascii-font-family:"Times New Roman";mso-hansi-font-family:"Times New Roman";
mso-char-type:symbol;mso-symbol-font-family:Symbol'><span style='mso-char-type:
symbol;mso-symbol-font-family:Symbol'>°</span></span><span style='font-size:
11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>C in dimethyl
sulfoxide and sparingly soluble in water and ethanol. The glutarimide moiety
contains a single asymmetric center and, therefore, may exist in either of two
optically active forms designated S-(-) or R-(+). THALOMID<sup>®</sup>
(thalidomide) is an equal mixture of the S-(-) and R-(+) forms and, therefore,
has a net optical rotation of zero.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>THALOMID<sup>®</sup>
(thalidomide) is available in 50 mg, 100 mg and 200 mg capsules for oral
administration. Active ingredient: thalidomide. Inactive ingredients:
pregelatinized starch and magnesium stearate. The 50 mg capsule shell contains
gelatin, titanium dioxide, and black ink. The 100 mg capsule shell contains
black iron oxide, yellow iron oxide, titanium dioxide, gelatin, and black
ink.<span style="mso-spacerun: yes">  </span>The 200 mg capsule shell contains
FD&amp;C blue #2, titanium dioxide, gelatin, and white ink.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:6.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>CLINICAL PHARMACOLOGY<o:p></o:p></span></b></p>

<p class=MsoPlainText style='margin-top:4.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Mechanism of Action<o:p></o:p></span></b></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Thalidomide is an
immunomodulatory agent with a spectrum of activity that is not fully
characterized. In patients with erythema nodosum leprosum (ENL) the mechanism
of action is not fully understood.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Available
data from <i style='mso-bidi-font-style:normal'>in vitro</i> studies and
preliminary clinical trials suggest that the immunologic effects of this compound
can vary substantially under different conditions, but may be related to
suppression of excessive tumor necrosis factor-alpha (TNF-</span><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:Symbol;
mso-ascii-font-family:"Times New Roman";mso-hansi-font-family:"Times New Roman";
mso-char-type:symbol;mso-symbol-font-family:Symbol'><span style='mso-char-type:
symbol;mso-symbol-font-family:Symbol'>a</span></span><span style='font-size:
11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>) production
and down-modulation of selected cell surface adhesion molecules involved in
leukocyte migration.<sup>3-6</sup> For example, administration of thalidomide
has been reported to decrease circulating levels of TNF-</span><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:Symbol;
mso-ascii-font-family:"Times New Roman";mso-hansi-font-family:"Times New Roman";
mso-char-type:symbol;mso-symbol-font-family:Symbol'><span style='mso-char-type:
symbol;mso-symbol-font-family:Symbol'>a</span></span><span style='font-size:
11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'> in patients
with ENL,<sup> 3</sup> however, it has also been shown to increase plasma TNF-</span><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:Symbol;
mso-ascii-font-family:"Times New Roman";mso-hansi-font-family:"Times New Roman";
mso-char-type:symbol;mso-symbol-font-family:Symbol'><span style='mso-char-type:
symbol;mso-symbol-font-family:Symbol'>a</span></span><span style='font-size:
11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'> levels in
HIV-seropositive patients.<sup>7</sup><o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:6.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Pharmacokinetics and
Drug Metabolism<o:p></o:p></span></b></p>

<p class=MsoPlainText style='margin-top:6.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:
normal'><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman"'>Absorption<o:p></o:p></span></i></b></p>

<p class=MsoPlainText style='margin-top:3.0pt;margin-right:0pt;margin-bottom:
3.0pt;margin-left:0pt;mso-list:skip'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'>The absolute bioavailability of
thalidomide from THALOMID<sup>®</sup> (thalidomide) capsules has not yet been
characterized in human subjects due to its poor aqueous solubility. In studies
of both healthy volunteers and subjects with Hansen’s disease, the mean time to
peak plasma concentrations (T<sub>max</sub>) of THALOMID<sup>®</sup>
(thalidomide) ranged from 2.9 to 5.7 hours indicating that THALOMID<sup>®</sup>
(thalidomide) is slowly absorbed from the gastrointestinal tract. While the
extent of absorption (as measured by area under the curve [AUC]) is
proportional to dose in healthy subjects, the observed peak concentration (C<sub>max</sub>)
increased in a less than proportional manner (see Table 1 below). This lack of
C<sub>max</sub> dose proportionality, coupled with the observed increase in T<sub>max</sub>
values, suggests that the poor solubility of thalidomide in aqueous media may
be hindering the rate of absorption.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;margin-right:0pt;margin-bottom:
3.0pt;margin-left:0pt;mso-list:skip'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;margin-right:0pt;margin-bottom:
3.0pt;margin-left:0pt;mso-list:skip'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;margin-right:0pt;margin-bottom:
3.0pt;margin-left:0pt;mso-list:skip'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<table border=1 cellspacing=0 cellpadding=0 style='margin-left:3.0pt;
 border-collapse:collapse;border:none;mso-border-alt:solid windowtext 3.0pt;
 mso-padding-alt:0pt 3.3pt 0pt 3.3pt'>
 <tr style='height:20.1pt;mso-row-margin-left:.3pt'>
  <td style='mso-cell-special:placeholder;border:none;padding:0pt 0pt 0pt 0pt'
  width=0><p class='MsoNormal'>&nbsp;</td>
  <td width=612 colspan=9 valign=top style='width:459.3pt;border:solid windowtext 1.5pt;
  padding:0pt 3.3pt 0pt 3.3pt;height:20.1pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip;
  tab-stops:36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>Table 1<o:p></o:p></span></b></p>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip;
  tab-stops:36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>Pharmacokinetic Parameter Values for THALOMID<sup>®</sup>
  (thalidomide)<o:p></o:p></span></b></p>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip;
  tab-stops:36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>Mean (%CV)<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style='height:20.1pt;mso-row-margin-left:.3pt'>
  <td style='mso-cell-special:placeholder;border:none;padding:0pt 0pt 0pt 0pt'
  width=0><p class='MsoNormal'>&nbsp;</td>
  <td width=148 colspan=2 valign=top style='width:111.0pt;border:none;
  border-left:solid windowtext 1.5pt;mso-border-top-alt:solid windowtext 1.5pt;
  padding:0pt 3.3pt 0pt 3.3pt;height:20.1pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>Population/<o:p></o:p></span></b></p>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>Single Dose<o:p></o:p></span></b></p>
  </td>
  <td width=140 colspan=3 valign=top style='width:105.3pt;border:none;
  mso-border-top-alt:solid windowtext 1.5pt;padding:0pt 3.3pt 0pt 3.3pt;
  height:20.1pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>AUC<sub>0</sub></span></b><b style='mso-bidi-font-weight:normal'><sub><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol;
  mso-ascii-font-family:"Times New Roman";mso-hansi-font-family:"Times New Roman";
  mso-char-type:symbol;mso-symbol-font-family:Symbol'><span style='mso-char-type:
  symbol;mso-symbol-font-family:Symbol'>¥</span></span></sub></b><b
  style='mso-bidi-font-weight:normal'><sub><span style='font-size:11.0pt;
  mso-bidi-font-size:12.0pt'> <o:p></o:p></span></sub></b></p>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>µg</span></b><span style='font-size:11.0pt;mso-bidi-font-size:12.0pt;
  font-family:Symbol;mso-ascii-font-family:"Times New Roman";mso-hansi-font-family:
  "Times New Roman";mso-char-type:symbol;mso-symbol-font-family:Symbol'><span
  style='mso-char-type:symbol;mso-symbol-font-family:Symbol'>·</span></span><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>hr/mL<o:p></o:p></span></b></p>
  </td>
  <td width=114 valign=top style='width:85.2pt;border:none;mso-border-top-alt:
  solid windowtext 1.5pt;padding:0pt 3.3pt 0pt 3.3pt;height:20.1pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>C<sub>max<o:p></o:p></sub></span></b></p>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>µg/mL<o:p></o:p></span></b></p>
  </td>
  <td width=96 valign=top style='width:72.0pt;border:none;mso-border-top-alt:
  solid windowtext 1.5pt;padding:0pt 3.3pt 0pt 3.3pt;height:20.1pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>T<sub>max</sub><o:p></o:p></span></b></p>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>(hrs)<o:p></o:p></span></b></p>
  </td>
  <td width=114 colspan=2 valign=top style='width:85.8pt;border:none;
  border-right:solid windowtext 1.5pt;mso-border-top-alt:solid windowtext 1.5pt;
  padding:0pt 3.3pt 0pt 3.3pt;height:20.1pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>Half&#8209;life<o:p></o:p></span></b></p>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>(hrs)</span></b><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='mso-row-margin-left:.3pt;mso-row-margin-right:.3pt'>
  <td style='mso-cell-special:placeholder;border:none;padding:0pt 0pt 0pt 0pt'
  width=0><p class='MsoNormal'>&nbsp;</td>
  <td width=612 colspan=8 valign=top style='width:459.0pt;border-top:none;
  border-left:solid windowtext 1.5pt;border-bottom:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.3pt 0pt 3.3pt'>
  <p class=MsoHeader style='mso-list:skip;tab-stops:36.0pt center 216.0pt right 432.0pt'><span
  style='font-size:11.0pt;mso-bidi-font-size:10.0pt'>Healthy Subjects (n=14)<o:p></o:p></span></p>
  </td>
  <td style='mso-cell-special:placeholder;border:none;padding:0pt 0pt 0pt 0pt'
  width=0><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='height:15.75pt;mso-row-margin-left:.3pt;mso-row-margin-right:.3pt'>
  <td style='mso-cell-special:placeholder;border:none;padding:0pt 0pt 0pt 0pt'
  width=0><p class='MsoNormal'>&nbsp;</td>
  <td width=150 colspan=3 valign=top style='width:112.5pt;border:none;
  border-left:solid windowtext 1.5pt;padding:0pt 3.3pt 0pt 3.3pt;height:15.75pt'>
  <p class=MsoNormal align=center style='margin-bottom:1.0pt;text-align:center;
  mso-list:skip'><span style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>50 mg<o:p></o:p></span></p>
  </td>
  <td width=138 valign=top style='width:103.5pt;border:none;padding:0pt 3.3pt 0pt 3.3pt;
  height:15.75pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>4.9 (16%)<o:p></o:p></span></p>
  </td>
  <td width=114 colspan=2 valign=top style='width:85.5pt;border:none;
  padding:0pt 3.3pt 0pt 3.3pt;height:15.75pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>0.62 (52%)<o:p></o:p></span></p>
  </td>
  <td width=96 valign=top style='width:72.0pt;border:none;padding:0pt 3.3pt 0pt 3.3pt;
  height:15.75pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>2.9 (66%)<o:p></o:p></span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.3pt 0pt 3.3pt;height:15.75pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>5.52 (37%)<o:p></o:p></span></p>
  </td>
  <td style='mso-cell-special:placeholder;border:none;padding:0pt 0pt 0pt 0pt'
  width=0><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='height:13.5pt;mso-row-margin-left:.3pt;mso-row-margin-right:.3pt'>
  <td style='mso-cell-special:placeholder;border:none;padding:0pt 0pt 0pt 0pt'
  width=0><p class='MsoNormal'>&nbsp;</td>
  <td width=150 colspan=3 valign=top style='width:112.5pt;border:none;
  border-left:solid windowtext 1.5pt;padding:0pt 3.3pt 0pt 3.3pt;height:13.5pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  mso-list:skip'><span style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>200
  mg<o:p></o:p></span></p>
  </td>
  <td width=138 valign=top style='width:103.5pt;border:none;padding:0pt 3.3pt 0pt 3.3pt;
  height:13.5pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>18.9 (17%)<o:p></o:p></span></p>
  </td>
  <td width=114 colspan=2 valign=top style='width:85.5pt;border:none;
  padding:0pt 3.3pt 0pt 3.3pt;height:13.5pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>1.76 (30%)<o:p></o:p></span></p>
  </td>
  <td width=96 valign=top style='width:72.0pt;border:none;padding:0pt 3.3pt 0pt 3.3pt;
  height:13.5pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>3.5 (57%)<o:p></o:p></span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.3pt 0pt 3.3pt;height:13.5pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>5.53 (25%)<o:p></o:p></span></p>
  </td>
  <td style='mso-cell-special:placeholder;border:none;padding:0pt 0pt 0pt 0pt'
  width=0><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='height:12.6pt;mso-row-margin-left:.3pt;mso-row-margin-right:.3pt'>
  <td style='mso-cell-special:placeholder;border:none;padding:0pt 0pt 0pt 0pt'
  width=0><p class='MsoNormal'>&nbsp;</td>
  <td width=150 colspan=3 valign=top style='width:112.5pt;border:none;
  border-left:solid windowtext 1.5pt;padding:0pt 3.3pt 0pt 3.3pt;height:12.6pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  mso-list:skip'><span style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>400
  mg<o:p></o:p></span></p>
  </td>
  <td width=138 valign=top style='width:103.5pt;border:none;padding:0pt 3.3pt 0pt 3.3pt;
  height:12.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>36.4 (26%)<o:p></o:p></span></p>
  </td>
  <td width=114 colspan=2 valign=top style='width:85.5pt;border:none;
  padding:0pt 3.3pt 0pt 3.3pt;height:12.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>2.82 (28%)<o:p></o:p></span></p>
  </td>
  <td width=96 valign=top style='width:72.0pt;border:none;padding:0pt 3.3pt 0pt 3.3pt;
  height:12.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>4.3 (37%)<o:p></o:p></span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.3pt 0pt 3.3pt;height:12.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>7.29 (36%)<o:p></o:p></span></p>
  </td>
  <td style='mso-cell-special:placeholder;border:none;padding:0pt 0pt 0pt 0pt'
  width=0><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='height:11.7pt;mso-row-margin-right:.3pt'>
  <td width=612 colspan=9 valign=top style='width:459.3pt;border-top:none;
  border-left:solid windowtext 1.5pt;border-bottom:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.3pt 0pt 3.3pt;height:11.7pt'>
  <p class=MsoNormal style='mso-list:skip'><span style='font-size:11.0pt;
  mso-bidi-font-size:12.0pt'>Patients with Hansen’s Disease<span
  style="mso-spacerun: yes">  </span>(n=6)<o:p></o:p></span></p>
  </td>
  <td style='mso-cell-special:placeholder;border:none;padding:0pt 0pt 0pt 0pt'
  width=0><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='mso-row-margin-right:.3pt'>
  <td width=148 colspan=2 valign=top style='width:111.0pt;border-top:none;
  border-left:solid windowtext 1.5pt;border-bottom:solid windowtext 1.5pt;
  border-right:none;padding:0pt 3.3pt 0pt 3.3pt'>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  mso-list:skip'><span style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>400
  mg<o:p></o:p></span></p>
  </td>
  <td width=140 colspan=3 valign=top style='width:105.3pt;border:none;
  border-bottom:solid windowtext 1.5pt;padding:0pt 3.3pt 0pt 3.3pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>46.4 (44.1%)<o:p></o:p></span></p>
  </td>
  <td width=114 colspan=2 valign=top style='width:85.5pt;border:none;
  border-bottom:solid windowtext 1.5pt;padding:0pt 3.3pt 0pt 3.3pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>3.44 (52.6%)<o:p></o:p></span></p>
  </td>
  <td width=96 valign=top style='width:72.0pt;border:none;border-bottom:solid windowtext 1.5pt;
  padding:0pt 3.3pt 0pt 3.3pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>5.7 (27%)<o:p></o:p></span></p>
  </td>
  <td width=114 valign=top style='width:85.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0pt 3.3pt 0pt 3.3pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>6.86 (17%)<o:p></o:p></span></p>
  </td>
  <td style='mso-cell-special:placeholder;border:none;padding:0pt 0pt 0pt 0pt'
  width=0><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <![if !supportMisalignedColumns]>
 <tr height=0>
  <td width=0 style='border:none'></td>
  <td width=148 style='border:none'></td>
  <td width=0 style='border:none'></td>
  <td width=2 style='border:none'></td>
  <td width=138 style='border:none'></td>
  <td width=0 style='border:none'></td>
  <td width=114 style='border:none'></td>
  <td width=96 style='border:none'></td>
  <td width=114 style='border:none'></td>
  <td width=0 style='border:none'></td>
 </tr>
 <![endif]>
</table>

<p class=MsoPlainText style='margin-top:4.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Coadministration
of THALOMID<sup>®</sup> (thalidomide) with a high fat meal causes minor
(&lt;10%) changes in the observed AUC and C<sub>max</sub> values; however, it
causes an increase in T<sub>max</sub> to approximately 6 hours.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:4.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Distribution</span></i></b><b
style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'><o:p></o:p></span></b></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>In human blood plasma,
the geometric mean plasma protein binding was 55% and 66%, respectively, for
(+)-(R)- and (-)-(S)-thalidomide.<sup>8</sup> In a pharmacokinetic study of
thalidomide in HIV-seropositive adult male subjects receiving thalidomide 100
mg/day, thalidomide was detectable in the semen. <o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:4.0pt;page-break-after:avoid;
mso-outline-level:1;mso-list:skip'><b style='mso-bidi-font-weight:normal'><i
style='mso-bidi-font-style:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'>Metabolism<o:p></o:p></span></i></b></p>

<p class=MsoPlainText style='page-break-after:avoid;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>At
the present time, the exact metabolic route and fate of thalidomide is not
known in humans. Thalidomide itself does not appear to be hepatically
metabolized to any large extent, but appears to undergo non-enzymatic
hydrolysis in plasma to multiple metabolites. In a repeat dose study in which
THALOMID<sup>®</sup> (thalidomide) 200 mg was administered to 10 healthy
females for 18 days, thalidomide displayed similar pharmacokinetic profiles on
the first and last day of dosing. This suggests that thalidomide does not
induce or inhibit its own metabolism. <o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:4.0pt;page-break-after:avoid;
mso-outline-level:1;mso-list:skip'><b style='mso-bidi-font-weight:normal'><i
style='mso-bidi-font-style:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'>Elimination<o:p></o:p></span></i></b></p>

<p class=MsoPlainText style='page-break-after:avoid;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>As
indicated in Table 1 (above) the mean half-life of elimination ranges from
approximately 5 to 7 hours following a single dose and is not altered upon
multiple dosing. As noted in the metabolism subsection, the precise metabolic
fate and route of elimination of thalidomide in humans is not known at this
time. Thalidomide itself has a renal clearance of 1.15 mL/minute with less than
0.7% of the dose excreted in the urine as unchanged drug. Following a single
dose, urinary levels of thalidomide were undetectable 48 hrs after dosing.
Although thalidomide is thought to be hydrolyzed to a number of metabolites,<sup>9</sup>
only a very small amount (0.02% of the administered dose) of 4-OH-thalidomide
was identified in the urine of subjects 12 to 24 hours after dosing. <o:p></o:p></span></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoPlainText style='mso-outline-level:1;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Pharmacokinetic
Data in Special Populations<o:p></o:p></span></i></b></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-list:skip'><i
style='mso-bidi-font-style:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'>HIV-seropositive Subjects:</span></i><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>
There is no apparent significant difference in measured pharmacokinetic
parameter values between healthy human subjects and HIV-seropositive subjects
following single dose administration of THALOMID<sup>®</sup> (thalidomide)
capsules.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><i
style='mso-bidi-font-style:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'>Patients with Hansen’s Disease:</span></i><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>
Analysis of data from a small study in Hansen’s patients suggests that these
patients, relative to healthy subjects, may have an increased bioavailability
of THALOMID<sup>®</sup> (thalidomide). The increase is reflected both in an
increased area under the curve and in increased peak plasma levels. The
clinical significance of this increase is unknown.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><i
style='mso-bidi-font-style:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'>Patients with Renal Insufficiency:</span></i><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>
The pharmacokinetics of thalidomide in patients with renal dysfunction have not
been determined.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><i
style='mso-bidi-font-style:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'>Patients with Hepatic Disease:</span></i><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>
The pharmacokinetics of thalidomide in patients with hepatic impairment have
not been determined.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><i
style='mso-bidi-font-style:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'>Age:</span></i><span style='font-size:
11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'> Analysis of
the data from pharmacokinetic studies in healthy volunteers and patients with
Hansen’s disease ranging in age from 20 to 69 years does not reveal any
age-related changes.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><i
style='mso-bidi-font-style:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'>Pediatric:</span></i><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>
No pharmacokinetic data are available in subjects below the age of 18 years.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><i
style='mso-bidi-font-style:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'>Gender:</span></i><span style='font-size:
11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'> While a
comparative trial of the effects of gender on thalidomide pharmacokinetics has
not been conducted, examination of the data for thalidomide does not reveal any
significant gender differences in pharmacokinetic parameter values.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><i
style='mso-bidi-font-style:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'>Race:</span></i><span style='font-size:
11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'> Pharmacokinetic
differences due to race have not been studied. <o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:6.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:
normal'><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman"'>Clinical Studies<o:p></o:p></span></i></b></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>The primary data
demonstrating the efficacy of thalidomide in the treatment of the cutaneous
manifestations of moderate to severe ENL are derived from the published medical
literature and from a retrospective study of 102 patients treated by the U.S.
Public Health Service.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Two
double-blind, randomized, controlled trials reported the dermatologic response
to a 7-day course of 100 mg thalidomide (four times daily) or control. Dosage
was lower for patients under 50 kg in weight.<o:p></o:p></span></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<div align=center>

<table border=1 cellspacing=0 cellpadding=0 style='border-collapse:collapse;
 border:none;mso-border-alt:solid windowtext 1.5pt;mso-padding-alt:0pt 3.9pt 0pt 3.9pt'>
 <tr style='height:20.1pt'>
  <td width=654 colspan=5 valign=top style='width:490.2pt;border:solid windowtext 1.5pt;
  padding:0pt 3.9pt 0pt 3.9pt;height:20.1pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip;
  tab-stops:36.0pt 72.0pt 108.0pt 144.0pt 180.0pt 216.0pt 252.0pt 288.0pt 324.0pt 360.0pt 396.0pt 432.0pt'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>Table 2<o:p></o:p></span></b></p>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>Double-Blind, Controlled Clinical Trials of Thalidomide in Patients
  with ENL:<o:p></o:p></span></b></p>
  <h1 style='mso-list:skip'><span style='font-size:11.0pt;mso-bidi-font-size:
  10.0pt'>Cutaneous Response<o:p></o:p></span></h1>
  </td>
 </tr>
 <tr style='height:20.1pt'>
  <td width=272 valign=top style='width:203.7pt;border:none;border-left:solid windowtext 1.5pt;
  mso-border-top-alt:solid windowtext 1.5pt;padding:0pt 3.9pt 0pt 3.9pt;
  height:20.1pt'>
  <h2 style='mso-list:skip'><span style='font-size:11.0pt;mso-bidi-font-size:
  10.0pt'>Reference<o:p></o:p></span></h2>
  </td>
  <td width=82 valign=top style='width:61.8pt;border:none;mso-border-top-alt:
  solid windowtext 1.5pt;padding:0pt 3.9pt 0pt 3.9pt;height:20.1pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>No. of Patients<o:p></o:p></span></b></p>
  </td>
  <td width=121 valign=top style='width:90.55pt;border:none;mso-border-top-alt:
  solid windowtext 1.5pt;padding:0pt 3.9pt 0pt 3.9pt;height:20.1pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>No. Treatment Courses*<o:p></o:p></span></b></p>
  </td>
  <td width=179 colspan=2 valign=top style='width:134.15pt;border:none;
  border-right:solid windowtext 1.5pt;mso-border-top-alt:solid windowtext 1.5pt;
  padding:0pt 3.9pt 0pt 3.9pt;height:20.1pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span lang=FR style='font-size:11.0pt;
  mso-bidi-font-size:12.0pt;mso-ansi-language:FR'>Percent Responding**<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style='height:20.1pt'>
  <td width=272 valign=top style='width:203.7pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.9pt 0pt 3.9pt;height:20.1pt'>
  <p class=MsoNormal style='mso-list:skip'><span lang=FR style='font-size:11.0pt;
  mso-bidi-font-size:12.0pt;mso-ansi-language:FR'>Iyer <i style='mso-bidi-font-style:
  normal'>et al.</i><sup>10</sup><o:p></o:p></span></p>
  <p class=MsoNormal style='mso-list:skip'><span style='font-size:11.0pt;
  mso-bidi-font-size:12.0pt'>Bull World Health Organization 1971;45:719<o:p></o:p></span></p>
  </td>
  <td width=82 valign=top style='width:61.8pt;border:none;padding:0pt 3.9pt 0pt 3.9pt;
  height:20.1pt'>
  <p class=MsoNormal style='mso-list:skip'><span style='font-size:11.0pt;
  mso-bidi-font-size:12.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>92<o:p></o:p></span></p>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><![if !supportEmptyParas]>&nbsp;<![endif]><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=121 valign=top style='width:90.55pt;border:none;padding:0pt 3.9pt 0pt 3.9pt;
  height:20.1pt'>
  <p class=MsoNormal style='mso-list:skip'><span style='font-size:11.0pt;
  mso-bidi-font-size:12.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>204<o:p></o:p></span></p>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><![if !supportEmptyParas]>&nbsp;<![endif]><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border:none;padding:0pt 3.9pt 0pt 3.9pt;
  height:20.1pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>Thalidomide<o:p></o:p></span></p>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>75%<o:p></o:p></span></p>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><![if !supportEmptyParas]>&nbsp;<![endif]><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=71 valign=top style='width:53.15pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.9pt 0pt 3.9pt;height:20.1pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>Aspirin<o:p></o:p></span></p>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>25%<o:p></o:p></span></p>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><![if !supportEmptyParas]>&nbsp;<![endif]><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:20.1pt'>
  <td width=272 valign=top style='width:203.7pt;border-top:none;border-left:
  solid windowtext 1.5pt;border-bottom:solid windowtext 1.5pt;border-right:
  none;padding:0pt 3.9pt 0pt 3.9pt;height:20.1pt'>
  <p class=MsoNormal style='mso-list:skip'><span lang=FR style='font-size:11.0pt;
  mso-bidi-font-size:12.0pt;mso-ansi-language:FR'>Sheskin<i style='mso-bidi-font-style:
  normal'> et al.</i></span><sup><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>11</span></sup><i style='mso-bidi-font-style:normal'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'> <o:p></o:p></span></i></p>
  <p class=MsoNormal style='margin-bottom:2.0pt;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>Int J Lep<i
  style='mso-bidi-font-style:normal'> </i>1969;37:135<o:p></o:p></span></p>
  </td>
  <td width=82 valign=top style='width:61.8pt;border:none;border-bottom:solid windowtext 1.5pt;
  padding:0pt 3.9pt 0pt 3.9pt;height:20.1pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>52<o:p></o:p></span></p>
  </td>
  <td width=121 valign=top style='width:90.55pt;border:none;border-bottom:solid windowtext 1.5pt;
  padding:0pt 3.9pt 0pt 3.9pt;height:20.1pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>173<o:p></o:p></span></p>
  </td>
  <td width=108 valign=top style='width:81.0pt;border:none;border-bottom:solid windowtext 1.5pt;
  padding:0pt 3.9pt 0pt 3.9pt;height:20.1pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>Thalidomide<o:p></o:p></span></p>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>66%<o:p></o:p></span></p>
  </td>
  <td width=71 valign=top style='width:53.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0pt 3.9pt 0pt 3.9pt;height:20.1pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>Placebo<o:p></o:p></span></p>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>10%<o:p></o:p></span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoPlainText align=center style='text-align:center;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>*In
patients with cutaneous lesions<o:p></o:p></span></p>

<p class=MsoPlainText align=center style='text-align:center;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>**Iyer:
Complete response or lesions absent<o:p></o:p></span></p>

<p class=MsoPlainText align=center style='text-align:center;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>**Sheskin:
Complete improvement + “striking” improvement (i.e., &gt;50% improvement)<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;margin-right:0pt;margin-bottom:
4.0pt;margin-left:0pt;mso-list:skip'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'>Waters<sup>12</sup> reported the results
of two studies, both double-blind, randomized, placebo-controlled, crossover
trials in a total of 10 hospitalized, steroid-dependent patients with chronic
ENL treated with 100 mg thalidomide or placebo (three times daily). All
patients also received dapsone. The primary endpoint was reduction in weekly
steroid dosage.<o:p></o:p></span></p>

<table border=1 cellspacing=0 cellpadding=0 style='margin-left:3.9pt;
 border-collapse:collapse;border:none;mso-border-alt:solid windowtext 1.5pt;
 mso-padding-alt:0pt 3.9pt 0pt 3.9pt'>
 <tr>
  <td width=636 colspan=5 valign=top style='width:477.0pt;border:solid windowtext 1.5pt;
  padding:0pt 3.9pt 0pt 3.9pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:10.0pt;
  mso-line-height-rule:exactly;mso-list:skip'><b style='mso-bidi-font-weight:
  normal'><span style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>Table 3<o:p></o:p></span></b></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:10.0pt;
  mso-line-height-rule:exactly;mso-list:skip'><b style='mso-bidi-font-weight:
  normal'><span style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>Double
  Blind, Controlled Trial of Thalidomide in Patients with ENL:<o:p></o:p></span></b></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:10.0pt;
  mso-line-height-rule:exactly;mso-list:skip'><b style='mso-bidi-font-weight:
  normal'><span style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>Reduction in
  Steroid Dosage<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr>
  <td width=144 valign=top style='width:107.7pt;border:none;border-left:solid windowtext 1.5pt;
  mso-border-top-alt:solid windowtext 1.5pt;padding:0pt 3.9pt 0pt 3.9pt'>
  <h2 style='mso-list:skip'><span style='font-size:11.0pt;mso-bidi-font-size:
  10.0pt'>Reference<o:p></o:p></span></h2>
  </td>
  <td width=156 valign=top style='width:117.3pt;border:none;mso-border-top-alt:
  solid windowtext 1.5pt;padding:0pt 3.9pt 0pt 3.9pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>Duration of<o:p></o:p></span></b></p>
  </td>
  <td width=132 valign=top style='width:98.7pt;border:none;mso-border-top-alt:
  solid windowtext 1.5pt;padding:0pt 3.9pt 0pt 3.9pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>No. of Patients<o:p></o:p></span></b></p>
  </td>
  <td width=204 colspan=2 valign=top style='width:153.3pt;border:none;
  border-right:solid windowtext 1.5pt;mso-border-top-alt:solid windowtext 1.5pt;
  padding:0pt 3.9pt 0pt 3.9pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>Number Responding<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr>
  <td width=144 valign=top style='width:107.7pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.9pt 0pt 3.9pt'>
  <p class=MsoNormal style='mso-list:skip'><![if !supportEmptyParas]>&nbsp;<![endif]><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'><o:p></o:p></span></b></p>
  </td>
  <td width=156 valign=top style='width:117.3pt;border:none;padding:0pt 3.9pt 0pt 3.9pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>Treatment<o:p></o:p></span></b></p>
  </td>
  <td width=132 valign=top style='width:98.7pt;border:none;padding:0pt 3.9pt 0pt 3.9pt'>
  <p class=MsoNormal style='mso-list:skip'><![if !supportEmptyParas]>&nbsp;<![endif]><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'><o:p></o:p></span></b></p>
  </td>
  <td width=102 valign=top style='width:76.5pt;border:none;padding:0pt 3.9pt 0pt 3.9pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>Thalidomide<o:p></o:p></span></b></p>
  </td>
  <td width=102 valign=top style='width:76.8pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.9pt 0pt 3.9pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>Placebo</span></b><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:14.85pt'>
  <td width=144 valign=top style='width:107.7pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.9pt 0pt 3.9pt;height:14.85pt'>
  <p class=MsoNormal style='mso-list:skip'><span style='font-size:11.0pt;
  mso-bidi-font-size:12.0pt'>Waters<sup>12</sup><o:p></o:p></span></p>
  </td>
  <td width=156 valign=top style='width:117.3pt;border:none;padding:0pt 3.9pt 0pt 3.9pt;
  height:14.85pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>4 weeks<o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:98.7pt;border:none;padding:0pt 3.9pt 0pt 3.9pt;
  height:14.85pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>9<o:p></o:p></span></p>
  </td>
  <td width=102 valign=top style='width:76.5pt;border:none;padding:0pt 3.9pt 0pt 3.9pt;
  height:14.85pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>4/5<o:p></o:p></span></p>
  </td>
  <td width=102 valign=top style='width:76.8pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.9pt 0pt 3.9pt;height:14.85pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>0/4<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:20.1pt'>
  <td width=144 valign=top style='width:107.7pt;border-top:none;border-left:
  solid windowtext 1.5pt;border-bottom:solid windowtext 1.5pt;border-right:
  none;padding:0pt 3.9pt 0pt 3.9pt;height:20.1pt'>
  <p class=MsoNormal style='mso-list:skip'><span style='font-size:11.0pt;
  mso-bidi-font-size:12.0pt'>Lep Rev 1971;42:26<o:p></o:p></span></p>
  </td>
  <td width=156 valign=top style='width:117.3pt;border:none;border-bottom:solid windowtext 1.5pt;
  padding:0pt 3.9pt 0pt 3.9pt;height:20.1pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>6 weeks (crossover)<o:p></o:p></span></p>
  </td>
  <td width=132 valign=top style='width:98.7pt;border:none;border-bottom:solid windowtext 1.5pt;
  padding:0pt 3.9pt 0pt 3.9pt;height:20.1pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>8<o:p></o:p></span></p>
  </td>
  <td width=102 valign=top style='width:76.5pt;border:none;border-bottom:solid windowtext 1.5pt;
  padding:0pt 3.9pt 0pt 3.9pt;height:20.1pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>8/8<o:p></o:p></span></p>
  </td>
  <td width=102 valign=top style='width:76.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0pt 3.9pt 0pt 3.9pt;height:20.1pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>1/8<o:p></o:p></span></p>
  </td>
 </tr>
</table>

<p class=MsoPlainText style='margin-top:3.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Data
on the efficacy of thalidomide in prevention of ENL relapse were derived from a
retrospective evaluation of 102 patients treated under the auspices of the U.S.
Public Health Service. A subset of patients with ENL controlled on thalidomide
demonstrated repeated relapse upon drug withdrawal and remission with
reinstitution of therapy.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Twenty
U.S. patients between the ages of 11 and 17 years were treated with
thalidomide, generally at 100 mg daily. Response rates and safety profiles were
similar to that observed in the adult population.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Thirty-two
other published studies containing over 1600 patients consistently report
generally successful treatment of the cutaneous manifestations of moderate to
severe ENL with thalidomide.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:6.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'>INDICATIONS AND USAGE</span></b><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><o:p></o:p></span></p>

<p class=MsoPlainText style='page-break-after:avoid;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>THALOMID<sup>®</sup>
(thalidomide) is indicated for the acute treatment of the cutaneous
manifestations of moderate to severe erythema nodosum leprosum (ENL).<span
style="mso-spacerun: yes">     </span><o:p></o:p></span></p>

<p class=MsoPlainText style='page-break-after:avoid;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>THALOMID<sup>®</sup>
(thalidomide) is not indicated as monotherapy for such ENL treatment in the
presence of moderate to severe neuritis. <o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>THALOMID<sup>®</sup>
(thalidomide) is also indicated as maintenance therapy for prevention and suppression
of the cutaneous manifestations of ENL recurrence.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:6.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'>CONTRAINDICATIONS (See BOXED WARNINGS.)<o:p></o:p></span></b></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Pregnancy: Category X <o:p></o:p></span></b></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Due to its known human
teratogenicity, even following a single dose, thalidomide is contraindicated in
pregnant women and women capable of becoming pregnant. (See <b
style='mso-bidi-font-weight:normal'>BOXED WARNINGS</b>.) When there is no
alternative treatment, women of childbearing potential may be treated with
thalidomide provided adequate precautions are taken to avoid pregnancy. Women
must commit either to abstain continuously from heterosexual sexual contact or
to use two methods of reliable birth control, including at least one highly
effective method (e.g., IUD, hormonal contraception, tubal ligation, or
partner’s vasectomy) and one additional effective method (e.g., latex condom,
diaphragm, or cervical cap), beginning 4 weeks prior to initiating treatment
with thalidomide, during therapy with thalidomide, and continuing for 4 weeks
following discontinuation of thalidomide therapy. If hormonal or IUD
contraception is medically contraindicated (see also <b style='mso-bidi-font-weight:
normal'>PRECAUTIONS: Drug Interactions</b>), two other effective or highly
effective methods may be used.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Women
of childbearing potential being treated with thalidomide should have a
pregnancy test (sensitivity of at least 50 mIU/mL). The test should be
performed within the 24 hours prior to<span style='color:red'> </span>beginning
thalidomide therapy and then weekly during the first 4 weeks<span
style='color:red'> </span>of thalidomide therapy, then at 4 week intervals in
women with regular menstrual cycles or every 2 weeks in women with irregular
menstrual cycles. Pregnancy testing and counseling should be performed if a
patient misses her period or if there is any abnormality in menstrual bleeding.
If pregnancy occurs during thalidomide treatment, thalidomide must be
discontinued immediately. Under these conditions, the patient should be
referred to an obstetrician/gynecologist experienced in reproductive toxicity
for further evaluation and counseling.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Because
thalidomide is present in the semen of patients receiving the drug, males
receiving thalidomide must always use a latex condom during any sexual contact
with women of childbearing potential.<span style='color:red'> </span><span
style='color:black'>The risk to the fetus from the semen of male patients
taking thalidomide is unknown.<o:p></o:p></span></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>THALOMID<sup>®</sup>
(thalidomide) is contraindicated in patients who have demonstrated
hypersensitivity to the drug and its components.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:6.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>WARNINGS (See BOXED
WARNINGS.)<span style="mso-spacerun: yes">                                 
</span><u><o:p></o:p></u></span></b></p>

<p class=MsoPlainText style='margin-top:4.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Birth Defects:<o:p></o:p></span></b></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Thalidomide
can cause severe birth defects in humans. (See <b style='mso-bidi-font-weight:
normal'>BOXED WARNINGS</b> and <b style='mso-bidi-font-weight:normal'>CONTRAINDICATIONS</b>.)
Patients should be instructed to take thalidomide only as prescribed and not to
share their thalidomide with anyone else. Because thalidomide is present in the
semen of patients receiving the drug, males receiving thalidomide must always
use a latex condom during any sexual contact with women of childbearing
potential.<span style='color:red'> </span><span style='color:black'>The risk to
the fetus from the semen of male patients taking thalidomide is unknown.<o:p></o:p></span></span></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman";color:red'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Drowsiness and
Somnolence:<o:p></o:p></span></b></p>

<p class=MsoPlainText style='page-break-after:avoid;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Thalidomide
frequently causes drowsiness and somnolence. Patients should be instructed to
avoid situations where drowsiness may be a problem and not to take other
medications that may cause drowsiness without adequate medical advice. Patients
should be advised as<span style="mso-spacerun: yes">   </span>to the possible
impairment of mental and/or physical abilities required for the performance of
hazardous tasks, such as driving a car or operating other complex or dangerous
machinery.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Peripheral Neuropathy:<o:p></o:p></span></b></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Thalidomide is known
to cause nerve damage that may be permanent. Peripheral neuropathy is a common,
potentially severe, side effect of treatment with thalidomide that may be
irreversible. Peripheral neuropathy generally occurs following chronic use over
a period of months<span style='color:red'>;</span> however, reports following
relatively short-term use also exist. The correlation with cumulative dose is
unclear. Symptoms may occur some time after thalidomide treatment has been
stopped and may resolve slowly or not at all. Few reports of neuropathy have
arisen in the treatment of ENL despite long-term thalidomide treatment.
However, the inability clinically to differentiate thalidomide neuropathy from
the neuropathy often seen in Hansen’s disease makes it difficult to determine
accurately the incidence of thalidomide-related neuropathy in ENL patients
treated with thalidomide.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Patients
should be examined at monthly intervals for the first 3 months of thalidomide
therapy to enable the clinician to detect early signs of neuropathy, which
include numbness, tingling or pain in the hands and feet. Patients should be
evaluated periodically thereafter during treatment. Patients should be
regularly counseled, questioned, and evaluated for signs or symptoms of
peripheral neuropathy. Consideration should be given to electrophysiological
testing, consisting of measurement of sensory nerve action potential (SNAP)
amplitudes at baseline and thereafter every 6 months in an effort to detect
asymptomatic neuropathy. If symptoms of drug-induced neuropathy develop,
thalidomide should be discontinued immediately to limit further damage, if
clinically appropriate. Usually, treatment with thalidomide should only be
reinitiated if the neuropathy returns to baseline status. Medications known to
be associated with neuropathy should be used with caution in patients receiving
thalidomide.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoPlainText style='mso-list:skip'><b style='mso-bidi-font-weight:
normal'><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman";color:black'>Thrombotic Events:<o:p></o:p></span></b></p>

<p class=MsoPlainText style='mso-list:skip'><b style='mso-bidi-font-weight:
normal'><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman";color:black'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></b></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman";color:black'>Thrombotic
events have been reported in patients treated with THALOMID<sup>®</sup>
(thalidomide).<span style="mso-spacerun: yes">  </span>Patients with neoplastic
and various inflammatory conditions being treated with THALOMID<sup>®</sup>
(thalidomide) may have an increased incidence of pulmonary embolism, deep vein
thrombophlebitis, thrombophlebitis, or thrombosis.<span style="mso-spacerun:
yes">  </span>It is not known if concomitant therapy with other medications
including anticancer agents, are a contributing factor.</span><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></b></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></b></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Dizziness and
Orthostatic Hypotension:<o:p></o:p></span></b></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Patients should also
be advised that thalidomide may cause dizziness and orthostatic hypotension and
that, therefore, they should sit upright for a few minutes prior to standing up
from a recumbent position. <o:p></o:p></span></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoPlainText style='mso-list:skip'><b style='mso-bidi-font-weight:
normal'><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman"'>Neutropenia:<span style="mso-spacerun:
yes">                                                             </span><u><o:p></o:p></u></span></b></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Decreased white blood
cell counts, including neutropenia, have been reported in association with the
clinical use of thalidomide. Treatment should not be initiated with an absolute
neutrophil count (ANC) of &lt;750/mm<sup>3</sup>. White blood cell count and
differential should be monitored on an ongoing basis, especially in patients
who may be more prone to neutropenia, such as patients who are
HIV-seropositive. If ANC decreases to below 750/mm<sup>3</sup> while on
treatment, the patient’s medication regimen should be re-evaluated and, if the
neutropenia persists, consideration should be given to withholding thalidomide
if clinically appropriate. <o:p></o:p></span></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoPlainText style='mso-list:skip'><b style='mso-bidi-font-weight:
normal'><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman"'>Increased HIV Viral Load:<o:p></o:p></span></b></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>In a randomized,
placebo controlled trial of thalidomide in an HIV-seropositive patient
population, plasma HIV RNA levels were found to increase (median change = 0.42
log<sub>10</sub> copies HIV RNA/mL, p = 0.04 compared to placebo). <sup>7</sup>
A similar trend was observed in a second, unpublished study conducted in
patients who were HIV- seropositive<sup>13</sup> The clinical significance of
this increase is unknown. Both studies were conducted prior to availability of
highly active antiretroviral therapy. Until the clinical significance of this
finding is further understood, in HIV-seropositive patients, viral load should
be measured after the first and third months of treatment and every 3 months
thereafter.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:6.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>PRECAUTIONS<o:p></o:p></span></b></p>

<p class=MsoPlainText style='margin-top:6.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman";color:black'>General:<o:p></o:p></span></b></p>

<p class=MsoPlainText style='margin-top:6.0pt;mso-outline-level:1;mso-list:
skip'><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";
color:black'>The only type of thalidomide exposure known to result in drug
associated birth defects are as a result of direct oral ingestion of
thalidomide.<span style="mso-spacerun: yes">  </span>Currently no specific data
are available regarding the cutaneous absorption or inhalation of thalidomide
in women of child-bearing potential and whether these exposures may result in
any birth defects.<span style="mso-spacerun: yes">  </span>Patients should be
instructed to not extensively handle or open THALOMID<sup>®</sup> (thalidomide)
Capsules and to maintain storage of capsules in blister packs until
ingestion.<span style="mso-spacerun: yes">  </span>If there is contact with
non-intact thalidomide capsules or the powder contents, the exposed area should
be washed with soap and water.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:6.0pt;mso-outline-level:1;mso-list:
skip'><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";
color:black'>Thalidomide has been shown to be present in the serum and semen of
patients receiving thalidomide.<span style="mso-spacerun: yes">  </span>If
healthcare providers or other care givers are exposed to body fluids from
patients receiving THALOMID<sup>® </sup>(thalidomide), appropriate precautions
should be utilized, such as wearing gloves to prevent the potential cutaneous
exposure to THALOMID<sup>® </sup>(thalidomide) or the exposed area should be
washed with soap and water.</span><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman";color:red'><o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:4.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Hypersensitivity:<o:p></o:p></span></b></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Hypersensitivity to
THALOMID<sup>®</sup> (thalidomide) has been reported. Signs and symptoms have
included the occurrence of erythematous macular rash, possibly associated with
fever, tachycardia, and hypotension, and if severe, may necessitate
interruption of therapy. If the reaction recurs when dosing is resumed,
THALOMID<sup>®</sup> (thalidomide) should be discontinued.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;page-break-after:avoid;
mso-outline-level:1;mso-list:skip'><b style='mso-bidi-font-weight:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Bradycardia:<o:p></o:p></span></b></p>

<p class=MsoPlainText style='page-break-after:avoid;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Bradycardia
in association with thalidomide use has been reported. <span style='color:black'>Cases
of bradycardia have been reported, some required medical interventions.</span><span
style='color:red'> </span>The clinical significance and underlying etiology of
the bradycardia noted in some thalidomide-treated patients are presently
unknown. <o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Stevens-Johnson Syndrome
and Toxic Epidermal Necrolysis:</span></b><b style='mso-bidi-font-weight:normal'><span
lang=FR style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";
mso-ansi-language:FR'><o:p></o:p></span></b></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Serious dermatologic
reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis,
which may be fatal, have been reported.<span style="mso-spacerun: yes"> 
</span>THALOMID<sup>®</sup> (thalidomide) should be discontinued if a skin rash
occurs and only resumed following appropriate clinical evaluation. If the rash
is exfoliative, purpuric, or bullous or if Stevens-Johnson syndrome or toxic
epidermal necrolysis is suspected, use of THALOMID<sup>®</sup> (thalidomide)
should not be resumed.<o:p></o:p></span></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoBodyText3 style='margin-top:3.0pt;mso-outline-level:1;mso-list:
skip;mso-layout-grid-align:auto;punctuation-wrap:hanging;text-autospace:ideograph-numeric ideograph-other'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt'>Seizures:<span
style="mso-spacerun: yes">                  </span><span style="mso-spacerun:
yes">                                  </span><u><o:p></o:p></u></span></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Although not reported
from pre-marketing controlled clinical trials, seizures, including grand mal
convulsions, have been reported during post-approval use of THALOMID</span><sup><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:Symbol;
mso-ascii-font-family:"Times New Roman";mso-hansi-font-family:"Times New Roman";
mso-char-type:symbol;mso-symbol-font-family:Symbol'><span style='mso-char-type:
symbol;mso-symbol-font-family:Symbol'>Ò</span></span></sup><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>
(thalidomide) in clinical practice. Because these events are reported
voluntarily from a population of unknown size, estimates of frequency cannot be
made. Most patients had disorders that may have predisposed them to seizure
activity, and it is not currently known whether thalidomide has any
epileptogenic influence. During therapy with thalidomide, patients with a
history of seizures or with other risk factors for the development of seizures
should be monitored closely for clinical changes that could precipitate acute
seizure activity.<b style='mso-bidi-font-weight:normal'><o:p></o:p></b></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Information for Patients
(See BOXED WARNINGS.)<o:p></o:p></span></b></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Patients should be
instructed about the potential teratogenicity of thalidomide and the
precautions that must be taken to preclude fetal exposure as per the <i
style='mso-bidi-font-style:normal'>S.T.E.P.S.</i><b style='mso-bidi-font-weight:
normal'><sup><span style='color:red'> </span>®</sup></b><sup> </sup>program and
boxed warnings in this package insert. Patients should be instructed to take
thalidomide only as prescribed in compliance with all of the provisions of the <i
style='mso-bidi-font-style:normal'>S.T.E.P.S.</i><b style='mso-bidi-font-weight:
normal'><sup><span style='color:red'> </span>®</sup></b> Restricted
Distribution Program.<o:p></o:p></span></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman";color:black'>Patients
should be instructed to not extensively handle or open THALOMID<sup>® </sup>(thalidomide)
Capsules and to maintain storage of capsules in blister packs until ingestion.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Patients
should be instructed not to share medication with anyone else.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Patients
should be instructed that thalidomide frequently causes drowsiness and
somnolence. Patients should be instructed to avoid situations where drowsiness
may be a problem and not to take other medications that may cause drowsiness
without adequate medical advice. Patients should be advised as to the possible
impairment of mental and/or physical abilities required for the performance of
hazardous tasks, such as driving a car or operating other complex machinery.
Patients should be instructed that thalidomide may potentiate the somnolence
caused by alcohol.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Patients
should be instructed that thalidomide can cause peripheral neuropathies that
may be initially signaled by numbness, tingling, or pain or a burning sensation
in the feet or hands. Patients should be instructed to report such occurrences
to their prescriber immediately. <o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Patients
should also be instructed that thalidomide may cause dizziness and orthostatic
hypotension and that, therefore, they should sit upright for a few minutes
prior to standing up from a recumbent position.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Patients
should be instructed that they are not permitted to donate blood while taking
thalidomide. In addition, male patients should be instructed that they are not
permitted to donate sperm while taking thalidomide.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:6.0pt;page-break-after:avoid;
mso-outline-level:1;mso-list:skip'><b style='mso-bidi-font-weight:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Laboratory
Tests<i style='mso-bidi-font-style:normal'><o:p></o:p></i></span></b></p>

<p class=MsoPlainText style='page-break-after:avoid;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Pregnancy
Testing:</span></i></b><b style='mso-bidi-font-weight:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>
(See BOXED WARNINGS.)</span></b><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'> Women of childbearing potential should
have a<span style='color:red'> </span>pregnancy test performed (sensitivity of
at least 50 mIU/mL). The test should be performed within the 24 hours prior to
beginning thalidomide therapy and then weekly during the first 4 weeks<span
style='color:red'> </span>of use, then at 4 week intervals in women with
regular menstrual cycles or every 2 weeks in women with irregular menstrual
cycles. Pregnancy testing and counseling should<span style="mso-spacerun:
yes">  </span>be performed if a patient misses her period or if there is any
abnormality in menstrual bleeding.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:
normal'><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman"'>Neutropenia:</span></i></b><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'> (<b style='mso-bidi-font-weight:
normal'>See WARNINGS</b>.)<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:
normal'><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman"'>Increased HIV Viral Load:</span></i></b><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>
(<b style='mso-bidi-font-weight:normal'>See WARNINGS</b>.) <span
style="mso-spacerun: yes">                                    </span><b
style='mso-bidi-font-weight:normal'><u><o:p></o:p></u></b></span></p>

<p class=MsoPlainText style='margin-top:4.0pt;page-break-after:avoid;
mso-outline-level:1;mso-list:skip'><b style='mso-bidi-font-weight:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Drug
Interactions<o:p></o:p></span></b></p>

<p class=MsoPlainText style='page-break-after:avoid;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Thalidomide
has been reported to enhance the sedative activity of barbiturates, alcohol,
chlorpromazine, and reserpine. <span style='color:red'><o:p></o:p></span></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Peripheral
Neuropathy:</span></i></b><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'> Medications known to be associated with
peripheral neuropathy should be used with caution in patients receiving
thalidomide.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Oral
Contraceptives:</span></i></b><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'> In 10 healthy women, the pharmacokinetic
profiles of norethindrone and ethinyl estradiol following administration of a
single dose containing 1.0 mg of norethindrone acetate and 75 µg of ethinyl
estradiol were studied. The results were similar with and without
coadministration of thalidomide 200 mg/day to steady-state levels.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:6.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><span lang=FR style='font-size:
11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";mso-ansi-language:
FR'>Important Non-Thalidomide Drug Interactions<o:p></o:p></span></b></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Drugs
That Interfere with Hormonal Contraceptives:</span></i></b><i style='mso-bidi-font-style:
normal'><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman"'> </span></i><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'>Concomitant use of HIV-protease
inhibitors, griseofulvin, <span style='color:black'>modafinil, pencillins,
rifampin, rifabutin, phenytoin, <s>or</s> carbamazepine, or certain herbal
supplements such as St. John’s Wort with hormonal contraceptive agents<s>,</s>
may reduce the effectiveness of the contraception and up to one month after
discontinuation of these concomitant therapies. Therefore, women requiring
treatment with one or more of these drugs must use two OTHER effective or
highly effective methods of contraception or abstain from heterosexual sexual
contact while taking thalidomide.<o:p></o:p></span></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Carcinogenesis,
Mutagenesis, Impairment of Fertility<i style='mso-bidi-font-style:normal'><o:p></o:p></i></span></b></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Long-term
carcinogenicity tests have not been conducted using thalidomide. Thalidomide
gave no evidence of mutagenic effects when assayed in <i style='mso-bidi-font-style:
normal'>in vitro</i> bacterial <i style='mso-bidi-font-style:normal'>(Salmonella
typhimurium</i> and <i style='mso-bidi-font-style:normal'>Escherichia coli</i>;
Ames mutagenicity test), <i style='mso-bidi-font-style:normal'>in vitro</i>
mammalian (AS52 Chinese hamster ovary cells; AS52/XPRT mammalian cell forward
gene mutation assay) and <i style='mso-bidi-font-style:normal'>in vivo</i>
mammalian (CD-1 mice; <i style='mso-bidi-font-style:normal'>in vivo</i>
micronucleus test) test systems. <o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Animal
studies to characterize the effects of thalidomide on fertility have not been
conducted.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:6.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Pregnancy<span
style="mso-spacerun:
yes">                                                               </span><u><o:p></o:p></u></span></b></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:
normal'><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman"'>Pregnancy Category X </span></i></b><b style='mso-bidi-font-weight:
normal'><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman"'><span style="mso-spacerun: yes"> </span>(See BOXED WARNING
and CONTRAINDICATIONS</span></b><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'>.<b style='mso-bidi-font-weight:normal'>)
</b><o:p></o:p></span></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Because of the known
human teratogenicity of thalidomide, thalidomide is contraindicated in women
who are or may become pregnant and who are not using the two required types of
birth control or who are not continually abstaining from heterosexual sexual
contact. If thalidomide is taken during pregnancy, it can cause severe birth
defects or death to an unborn baby. Thalidomide should never be used by women
who are pregnant or who could become pregnant while taking the drug. Even a
single dose [1 capsule (50 mg, 100 mg, or a 200 mg)] taken by a pregnant woman
can cause birth defects. If pregnancy does occur during treatment, the drug
should be immediately discontinued. Under these conditions, the patient should
be referred to an obstetrician/gynecologist experienced in reproductive
toxicity for further evaluation and counseling. Any suspected fetal exposure to
THALOMID<sup>®</sup> (thalidomide) must be reported to the FDA <i
style='mso-bidi-font-style:normal'>via</i> the MedWatch program at
1-800-FDA-1088 and also to Celgene Corporation.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Because
thalidomide is present in the semen of patients receiving the drug, males
receiving thalidomide must always use a latex condom during any sexual contact
with women of childbearing potential. <span style='color:black'>The risk to the
fetus from the semen of male patients taking thalidomide is unknown.<o:p></o:p></span></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Animal
studies to characterize the effects of thalidomide on late<span
style='color:red'>-</span>stage pregnancy have not been conducted.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:4.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Use in Nursing Mothers<o:p></o:p></span></b></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>It is not known
whether thalidomide is excreted in human milk. Because many drugs are excreted
in human milk and because of the potential for serious adverse reactions in
nursing infants from thalidomide, a decision should be made whether to
discontinue nursing or to discontinue the drug, taking into account the
importance of the drug to the mother.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:4.0pt;page-break-after:avoid;
mso-outline-level:1;mso-list:skip'><b style='mso-bidi-font-weight:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Pediatric
Use<o:p></o:p></span></b></p>

<p class=MsoPlainText style='page-break-after:avoid;mso-outline-level:1;
mso-list:skip'><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;
font-family:"Times New Roman"'>Safety and effectiveness in pediatric patients
below the age of 12 years have not been established.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:4.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Geriatric Use<o:p></o:p></span></b></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>No systematic studies
in geriatric patients have been conducted. Thalidomide has been used in
clinical trials in patients up to 90 years of age. Adverse events in patients over
the age of 65 years did not appear to differ in kind from those reported for
younger individuals.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:6.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>ADVERSE REACTIONS<o:p></o:p></span></b></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>The most serious
toxicity associated with thalidomide is its documented human teratogenicity.
(See <b style='mso-bidi-font-weight:normal'>BOXED WARNINGS</b> and <b
style='mso-bidi-font-weight:normal'>CONTRAINDICATIONS.</b>) The risk of severe
birth defects, primarily phocomelia or death to the fetus, is extremely high
during the critical period of pregnancy. The critical period is estimated,
depending on the source of information, to range from 35 to 50 days after the
last menstrual period. The risk of other potentially severe birth defects
outside this critical period is unknown, but may be significant. Based on
present knowledge, thalidomide must not be used at any time during pregnancy.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Because
thalidomide is present in the semen of patients receiving the drug, males
receiving thalidomide must always use a latex condom during any sexual contact
with women of childbearing potential.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Thalidomide
is associated with drowsiness/somnolence, peripheral neuropathy,
dizziness/orthostatic hypotension, neutropenia, and HIV viral load increase.
(See<b style='mso-bidi-font-weight:normal'> WARNINGS</b>.)<span
style="mso-spacerun: yes">  </span><o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Hypersensitivity
to THALOMID<sup>®</sup> (thalidomide) and bradycardia in patients treated with
thalidomide have been reported. (See <b style='mso-bidi-font-weight:normal'>PRECAUTIONS</b>.)<span
style="mso-spacerun: yes">                </span><b style='mso-bidi-font-weight:
normal'><u><o:p></o:p></u></b></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Somnolence,
dizziness, and rash are the most commonly observed adverse events associated
with the use of thalidomide. Thalidomide has been studied in controlled and
uncontrolled clinical trials in patients with ENL and in people who are
HIV-seropositive. In addition, thalidomide has been administered
investigationally for more than 20 years in numerous indications. Adverse event
profiles from these uses are summarized in the sections that follow.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:4.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Other Adverse Events<o:p></o:p></span></b></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Due to the nature of
the longitudinal data that form the basis of this product’s safety evaluation,
no determination has been made of the causal relationship between the reported
adverse events listed below and thalidomide. These lists are of various adverse
events noted by investigators in patients to whom they had administered
thalidomide under various conditions. <span style='color:black'>The use of
thalidomide may not limit disease progression and/or death.</span><span
style='color:red'><o:p></o:p></span></span></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoPlainText style='mso-outline-level:1;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'>Incidence in Controlled Clinical Trials <o:p></o:p></span></b></p>

<p class=MsoPlainText style='margin-bottom:3.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Table
4 lists treatment-emergent signs and symptoms that occurred in THALOMID<sup>®</sup>
(thalidomide)-treated patients in controlled clinical trials in ENL. Doses
ranged from 50 to 300 mg/day. All adverse events were mild to moderate in
severity, and none resulted in discontinuation. Table 4 also lists
treatment-emergent adverse events that occurred in at least three of the
THALOMID<sup>®</sup> (thalidomide)-treated HIV-seropositive patients who
participated in an 8-week, placebo-controlled clinical trial. Events that were
more frequent in the placebo-treated group are not included. (See<b
style='mso-bidi-font-weight:normal'> WARNINGS, PRECAUTIONS,</b> and <b
style='mso-bidi-font-weight:normal'>Drug<span style='color:red'> </span>I</b>nteractions.)<span
style="mso-spacerun: yes">            </span><o:p></o:p></span></p>

<div align=center>

<table border=0 cellspacing=0 cellpadding=0 style='border-collapse:collapse;
 mso-padding-alt:0pt 3.45pt 0pt 3.45pt'>
 <tr style='height:25.5pt'>
  <td width=596 colspan=5 valign=top style='width:446.9pt;border:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:25.5pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:10.0pt;
  mso-line-height-rule:exactly;mso-list:skip'><span style='font-size:9.0pt;
  mso-bidi-font-size:12.0pt'><span style="mso-spacerun:
  yes">                                   </span><b style='mso-bidi-font-weight:
  normal'>Table 4<o:p></o:p></b></span></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:10.0pt;
  mso-line-height-rule:exactly;mso-list:skip'><b style='mso-bidi-font-weight:
  normal'><span style='font-size:9.0pt;mso-bidi-font-size:12.0pt'>Summary of
  Adverse Events (AEs)<o:p></o:p></span></b></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:10.0pt;
  mso-line-height-rule:exactly;mso-list:skip'><b style='mso-bidi-font-weight:
  normal'><span style='font-size:9.0pt;mso-bidi-font-size:12.0pt'>Reported in
  Celgene-sponsored Controlled Clinical Trials</span></b><b style='mso-bidi-font-weight:
  normal'><span style='font-size:8.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  mso-border-top-alt:solid windowtext 1.5pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal style='mso-list:skip'><![if !supportEmptyParas]>&nbsp;<![endif]><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;border:none;mso-border-top-alt:
  solid windowtext 1.5pt;padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:10.0pt;
  mso-line-height-rule:exactly;mso-list:skip'><b style='mso-bidi-font-weight:
  normal'><span style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>All AEs
  Reported</span></b><span style='font-size:8.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=281 colspan=3 valign=top style='width:210.85pt;border:none;
  border-right:solid windowtext 1.5pt;mso-border-top-alt:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <h3 style='line-height:10.0pt;mso-line-height-rule:exactly;page-break-after:
  auto;mso-list:skip;mso-layout-grid-align:auto;punctuation-wrap:hanging;
  text-autospace:ideograph-numeric ideograph-other'><span style='font-size:
  8.0pt;mso-bidi-font-size:10.0pt'>AEs Reported in </span><span
  style='font-size:8.0pt;mso-bidi-font-size:10.0pt;font-family:Symbol;
  mso-ascii-font-family:"Times New Roman";mso-hansi-font-family:"Times New Roman";
  mso-char-type:symbol;mso-symbol-font-family:Symbol'><span style='mso-char-type:
  symbol;mso-symbol-font-family:Symbol'>³</span></span><span style='font-size:
  8.0pt;mso-bidi-font-size:10.0pt'>3 HIV-seropositive Patients<o:p></o:p></span></h3>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoHeading8>Body System/Adverse Event</p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'>in ENL Patients</span></b><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=168 colspan=2 valign=top style='width:126.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'>Thalidomide</span></b><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'>Placebo</span></b><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='mso-list:skip'><![if !supportEmptyParas]>&nbsp;<![endif]><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:10.0pt;
  mso-line-height-rule:exactly;mso-list:skip'><b style='mso-bidi-font-weight:
  normal'><span style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>50 to 300
  mg/day<o:p></o:p></span></b></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:10.0pt;
  mso-line-height-rule:exactly;mso-list:skip'><b style='mso-bidi-font-weight:
  normal'><span style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>(N=24)</span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:10.0pt;
  mso-line-height-rule:exactly;mso-list:skip'><b style='mso-bidi-font-weight:
  normal'><span style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>100 mg/day<o:p></o:p></span></b></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:10.0pt;
  mso-line-height-rule:exactly;mso-list:skip'><b style='mso-bidi-font-weight:
  normal'><span style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>(N=36)</span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:10.0pt;
  mso-line-height-rule:exactly;mso-list:skip'><b style='mso-bidi-font-weight:
  normal'><span style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>200 mg/day<o:p></o:p></span></b></p>
  <p class=MsoNormal align=center style='text-align:center;line-height:10.0pt;
  mso-line-height-rule:exactly;mso-list:skip'><b style='mso-bidi-font-weight:
  normal'><span style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>(N=32)</span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='mso-list:skip'><b style='mso-bidi-font-weight:normal'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></b></p>
  <p class=MsoNormal align=center style='margin-bottom:2.0pt;text-align:center;
  mso-list:skip'><b style='mso-bidi-font-weight:normal'><span style='font-size:
  8.0pt;mso-bidi-font-size:12.0pt'>(N=35)</span></b><span style='font-size:
  8.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <h4 style='mso-list:skip'><span style='font-size:8.0pt;mso-bidi-font-size:
  10.0pt'>Body as a Whole<o:p></o:p></span></h4>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:10.0pt;
  mso-line-height-rule:exactly;mso-list:skip'><b style='mso-bidi-font-weight:
  normal'><span style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>16 (66.7%)</span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:10.0pt;
  mso-line-height-rule:exactly;mso-list:skip'><b style='mso-bidi-font-weight:
  normal'><span style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>18 (50.0%)</span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:10.0pt;
  mso-line-height-rule:exactly;mso-list:skip'><b style='mso-bidi-font-weight:
  normal'><span style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>19 (59.4%)</span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:10.0pt;
  mso-line-height-rule:exactly;mso-list:skip'><b style='mso-bidi-font-weight:
  normal'><span style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>13 (37.1%)</span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Abdominal pain<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (4.2%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (2.8%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (3.1%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>4 (11.4%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Accidental injury<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (4.2%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>2 (5.6%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (2.9%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Asthenia<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>2 (8.3%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>2 (5.6%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>7 (21.9%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (2.9%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Back pain<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (4.2%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>2 (5.6%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Chills<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (4.2%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>3 (9.4%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>4 (11.4%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Facial edema<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (4.2%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Fever<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>7 (19.4%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>7 (21.9%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>6 (17.1%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Headache<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>3 (12.5%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>6 (16.7%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>6 (18.7%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>4 (11.4%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Infection<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>3 (8.3%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>2 (6.3%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (2.9%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Malaise<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>2 (8.3%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Neck pain<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (4.2%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Neck rigidity<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (4.2%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Pain<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>2 (8.3%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (3.1%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>2 (5.7%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='mso-list:skip'><b style='mso-bidi-font-weight:normal'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Digestive System</span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:10.0pt;
  mso-line-height-rule:exactly;mso-list:skip'><b style='mso-bidi-font-weight:
  normal'><span style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>5 (20.8%)</span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:10.0pt;
  mso-line-height-rule:exactly;mso-list:skip'><b style='mso-bidi-font-weight:
  normal'><span style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>16 (44.4%)</span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:10.0pt;
  mso-line-height-rule:exactly;mso-list:skip'><b style='mso-bidi-font-weight:
  normal'><span style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>16 (50.0%)</span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:10.0pt;
  mso-line-height-rule:exactly;mso-list:skip'><b style='mso-bidi-font-weight:
  normal'><span style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>15 (42.9%)</span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Anorexia<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (2.8%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>3 (9.4%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>2 (5.7%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Constipation<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (4.2%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (2.8%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>3 (9.4%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Diarrhea<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (4.2%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>4 (11.1%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>6 (18.7%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>6 (17.1%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Dry mouth<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>3 (8.3%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>3 (9.4%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>2 (5.7%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Flatulence<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>3 (8.3%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>2 (5.7%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.1pt;line-height:8.0pt;mso-line-height-rule:
  exactly;mso-list:skip'><span style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Liver
  function tests multiple abnormalities<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>3 (9.4%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Nausea<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (4.2%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>4 (12.5%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (2.9%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Oral moniliasis<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (4.2%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>4 (11.1%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>2 (6.3%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Tooth pain<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (4.2%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='mso-list:skip'><b style='mso-bidi-font-weight:normal'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Hemic and Lymphatic</span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:10.0pt;
  mso-line-height-rule:exactly;mso-list:skip'><b style='mso-bidi-font-weight:
  normal'><span style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0</span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:10.0pt;
  mso-line-height-rule:exactly;mso-list:skip'><b style='mso-bidi-font-weight:
  normal'><span style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>8 (22.2%)</span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:10.0pt;
  mso-line-height-rule:exactly;mso-list:skip'><b style='mso-bidi-font-weight:
  normal'><span style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>13 (40.6%)</span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:10.0pt;
  mso-line-height-rule:exactly;mso-list:skip'><b style='mso-bidi-font-weight:
  normal'><span style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>10 (28.6%)</span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Anemia<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>2 (5.6%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>4 (12.5%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>3 (8.6%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Leukopenia<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>6 (16.7%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>8 (25.0%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>3 (8.6%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Lymphadenopathy<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>2 (5.6%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>4 (12.5%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>3 (8.6%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='mso-list:skip'><b style='mso-bidi-font-weight:normal'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Metabolic and Endocrine
  Disorders</span></b><span style='font-size:8.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'>1 (4.2%)</span></b><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'>8 (22.2%)</span></b><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'>12 (37.5%)</span></b><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'>8 (22.9%)</span></b><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Edema peripheral<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (4.2%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>3 (8.3%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (3.1%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Hyperlipemia<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>2 (5.6%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>3 (9.4%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (2.9%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>SGOT increased<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (2.8%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>4 (12.5%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>2 (5.7%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='mso-list:skip'><b style='mso-bidi-font-weight:normal'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Nervous System</span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span lang=FR style='font-size:8.0pt;
  mso-bidi-font-size:12.0pt;mso-ansi-language:FR'>13 (54.2%)</span></b><span
  lang=FR style='font-size:8.0pt;mso-bidi-font-size:12.0pt;mso-ansi-language:
  FR'><o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span lang=FR style='font-size:8.0pt;
  mso-bidi-font-size:12.0pt;mso-ansi-language:FR'>19 (52.8%)</span></b><span
  lang=FR style='font-size:8.0pt;mso-bidi-font-size:12.0pt;mso-ansi-language:
  FR'><o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span lang=FR style='font-size:8.0pt;
  mso-bidi-font-size:12.0pt;mso-ansi-language:FR'>18 (56.3%)</span></b><span
  lang=FR style='font-size:8.0pt;mso-bidi-font-size:12.0pt;mso-ansi-language:
  FR'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span lang=FR style='font-size:8.0pt;
  mso-bidi-font-size:12.0pt;mso-ansi-language:FR'>12 (34.3%)</span></b><span
  lang=FR style='font-size:8.0pt;mso-bidi-font-size:12.0pt;mso-ansi-language:
  FR'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span lang=FR
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt;mso-ansi-language:FR'>Agitation<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  lang=FR style='font-size:8.0pt;mso-bidi-font-size:12.0pt;mso-ansi-language:
  FR'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  lang=FR style='font-size:8.0pt;mso-bidi-font-size:12.0pt;mso-ansi-language:
  FR'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  lang=FR style='font-size:8.0pt;mso-bidi-font-size:12.0pt;mso-ansi-language:
  FR'>3 (9.4%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  lang=FR style='font-size:8.0pt;mso-bidi-font-size:12.0pt;mso-ansi-language:
  FR'>0<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span lang=FR
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt;mso-ansi-language:FR'>Dizziness<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  lang=FR style='font-size:8.0pt;mso-bidi-font-size:12.0pt;mso-ansi-language:
  FR'>1 (4.2%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  lang=FR style='font-size:8.0pt;mso-bidi-font-size:12.0pt;mso-ansi-language:
  FR'>7 (19.4%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  lang=FR style='font-size:8.0pt;mso-bidi-font-size:12.0pt;mso-ansi-language:
  FR'>6 (18.7%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  lang=FR style='font-size:8.0pt;mso-bidi-font-size:12.0pt;mso-ansi-language:
  FR'>0<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span lang=FR
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt;mso-ansi-language:FR'>Insomnia<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>3 (9.4%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>2 (5.7%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Nervousness<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (2.8%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>3 (9.4%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Neuropathy<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>3 (8.3%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Paresthesia<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>2 (5.6%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>5 (15.6%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>4 (11.4%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Somnolence<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>9 (37.5%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>13 (36.1%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>12 (37.5%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>4 (11.4%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Tremor<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (4.2%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Vertigo<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>2 (8.3%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='mso-list:skip'><b style='mso-bidi-font-weight:normal'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Respiratory System</span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'>3 (12.5%)</span></b><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'>9 (25.0%)</span></b><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'>6 (18.7%)</span></b><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'>9 (25.7%)</span></b><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Pharyngitis<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (4.2%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>3 (8.3%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>2 (6.3%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>2 (5.7%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Rhinitis<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (4.2%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>4 (11.4%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Sinusitis<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (4.2%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>3 (8.3%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (3.1%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>2 (5.7%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='mso-list:skip'><b style='mso-bidi-font-weight:normal'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Skin and Appendages</span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'>10 (41.7%)</span></b><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'>17 (47.2%)</span></b><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'>18 (56.3%)</span></b><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'>19 (54.3%)</span></b><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Acne<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>4 (11.1%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (3.1%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Dermatitis fungal<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (4.2%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>2 (5.6%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>3 (9.4%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Nail disorder<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (4.2%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (3.1%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Pruritus<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>2 (8.3%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (2.8%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>2 (6.3%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>2 (5.7%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Rash<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>5 (20.8%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>9 (25.0%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>8 (25.0%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>11 (31.4%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Rash maculo&#8209;papular<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (4.2%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>6 (16.7%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>6 (18.7%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>2 (5.7%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Sweating<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>4 (12.5%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>4 (11.4%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='mso-list:skip'><b style='mso-bidi-font-weight:normal'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Urogenital System</span></b><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'>2 (8.3%)</span></b><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'>6 (16.7%)</span></b><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'>2 (6.3%)</span></b><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'><o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'>4 (11.4%)</span></b><span style='font-size:8.0pt;mso-bidi-font-size:
  12.0pt'><o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Albuminuria<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>3 (8.3%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (3.1%)<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>2 (5.7%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border:none;border-left:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Hematuria<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>4 (11.1%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;padding:0pt 3.45pt 0pt 3.45pt;
  height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border:none;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (2.9%)<o:p></o:p></span></p>
  </td>
 </tr>
 <tr style='height:3.6pt'>
  <td width=195 valign=top style='width:146.05pt;border-top:none;border-left:
  solid windowtext 1.5pt;border-bottom:solid windowtext 1.5pt;border-right:
  none;padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal style='margin-left:10.05pt;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>Impotence<o:p></o:p></span></p>
  </td>
  <td width=120 valign=top style='width:90.0pt;border:none;border-bottom:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>2 (8.3%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border:none;border-bottom:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>1 (2.8%)<o:p></o:p></span></p>
  </td>
  <td width=84 valign=top style='width:63.0pt;border:none;border-bottom:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
  <td width=113 valign=top style='width:84.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.5pt;border-right:solid windowtext 1.5pt;
  padding:0pt 3.45pt 0pt 3.45pt;height:3.6pt'>
  <p class=MsoNormal align=center style='text-align:center;mso-list:skip'><span
  style='font-size:8.0pt;mso-bidi-font-size:12.0pt'>0<o:p></o:p></span></p>
  </td>
 </tr>
</table>

</div>

</div>

<b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman";mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language:EN-US;
mso-bidi-language:AR-SA'><br clear=all style='page-break-before:always;
mso-break-type:section-break'>
</span></b>

<div class=Section2>

<p class=MsoPlainText style='mso-list:skip'><b style='mso-bidi-font-weight:
normal'><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman"'>Other Adverse Events Observed in ENL Patients<o:p></o:p></span></b></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Thalidomide in doses
up to 400 mg/day has been administered investigationally in the United States
over a 19-year period in 1465 patients with ENL. The published literature
describes the treatment of an additional 1678 patients. To provide a meaningful
estimate of the proportion of the individuals having adverse events, similar
types of events were grouped into a smaller number of standardized categories
using a modified COSTART dictionary/terminology. These categories are used in
the listing below. All reported events are included except those already listed
in the previous table. Due to the fact that these data were collected from
uncontrolled studies, the incidence rate cannot be determined. As mentioned
previously, <b style='mso-bidi-font-weight:normal'>no causal relationship
between thalidomide and these events can be conclusively determined at this
time</b>. These are reports of all adverse events noted by investigators in
patients to whom they had administered thalidomide. <o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Body
as a Whole:</span></i></b><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'> Abdomen enlarged, fever,
photosensitivity, upper extremity pain.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Cardiovascular
System</span></i></b><b style='mso-bidi-font-weight:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>:</span></b><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>
Bradycardia, hypertension, hypotension, peripheral vascular disorder,
tachycardia<span style='color:red'>, </span>vasodilation.<span
style='color:red'><o:p></o:p></span></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Digestive
System:</span></i></b><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;
font-family:"Times New Roman"'> Anorexia, appetite increase/weight gain, dry mouth,
dyspepsia, enlarged liver, eructation, flatulence, increased liver function
tests, intestinal obstruction, vomiting.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Hemic
and Lymphatic:</span></i></b><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'> ESR decrease, eosinophilia,
granulocytopenia, hypochromic anemia, leukemia, leukocytosis, leukopenia, MCV
elevated, RBC abnormal, spleen palpable, thrombocytopenia.<span
style='color:red'><o:p></o:p></span></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Metabolic
and Endocrine:</span></i></b><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'> ADH inappropriate,<s> </s>amyloidosis,
bilirubinemia, BUN increased, creatinine increased, cyanosis, diabetes, edema,
electrolyte abnormalities, hyperglycemia, hyperkalemia, hyperuricemia,
hypocalcemia, hypoproteinemia, LDH increased, phosphorus decreased, SGPT
increased.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Muscular
Skeletal:</span></i></b><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;
font-family:"Times New Roman"'> Arthritis, bone tenderness, hypertonia, joint
disorder, leg cramps, myalgia, myasthenia, periosteal disorder.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Nervous
System:</span></i></b><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;
font-family:"Times New Roman"'> Abnormal thinking, agitation, amnesia, anxiety,
causalgia, circumoral paresthesia, confusion, depression, euphoria,
hyperesthesia, insomnia, nervousness, neuralgia, neuritis, neuropathy,
paresthesia, peripheral neuritis, psychosis.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Respiratory
System:</span></i></b><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;
font-family:"Times New Roman"'> Cough, emphysema, epistaxis, pulmonary embolus,
rales, upper respiratory infection, voice alteration.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Skin
and Appendages:</span></i></b><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'> Acne, alopecia, dry skin, eczematous
rash, exfoliative dermatitis, ichthyosis, perifollicular thickening, skin
necrosis, seborrhea, sweating, urticaria, vesiculobullous rash.<o:p></o:p></span></p>

<p class=MsoNormal style='mso-list:skip'><b style='mso-bidi-font-weight:normal'><i
style='mso-bidi-font-style:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
12.0pt'>Special Senses:</span></i></b><span style='font-size:11.0pt;mso-bidi-font-size:
12.0pt'> Amblyopia, deafness, dry eye, eye pain, tinnitus.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Urogenital:</span></i></b><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>
Decreased creatinine clearance, hematuria, orchitis, proteinuria, pyuria,
urinary frequency.<o:p></o:p></span></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoPlainText style='mso-outline-level:1;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'>Other Adverse Events Observed in
HIV-seropositive Patients<span style="mso-spacerun: yes">          </span><span
style="mso-spacerun: yes">              </span><u><o:p></o:p></u></span></b></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>In addition to
controlled clinical trials, THALOMID<sup>®</sup> (thalidomide) has been used in
uncontrolled studies in 145 patients. Less frequent adverse events that have
been reported in these HIV-seropositive patients treated with THALOMID<sup>®</sup>
(thalidomide) were grouped into a smaller number of standardized categories
using modified COSTART dictionary/terminology and these categories are used in
the listing below. Adverse events that have already been included in the tables
and narrative above, or that are too general to be informative are not listed.<o:p></o:p></span></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Body
as a Whole:</span></i></b><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'> Ascites, AIDS, allergic reaction,
cellulitis, chest pain, chills and fever, cyst, decreased CD4 count, facial
edema, flu syndrome, hernia, <span style='color:black'>thyroid</span><span
style='color:red'> </span>hormone level altered, moniliasis, photosensitivity
reaction, sarcoma, sepsis, viral infection. <o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Cardiovascular
System:</span></i></b><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;
font-family:"Times New Roman"'> Angina pectoris, arrhythmia, atrial
fibrillation, bradycardia, cerebral ischemia, cerebrovascular accident,
congestive heart failure, deep thrombophlebitis, heart arrest, heart failure,
hypertension, hypotension, murmur, myocardial infarct, palpitation,
pericarditis, peripheral vascular disorder, postural hypotension, syncope,
tachycardia, thrombophlebitis, thrombosis.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Digestive
System:</span></i></b><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;
font-family:"Times New Roman"'> Cholangitis, cholestatic jaundice, colitis,
dyspepsia, dysphagia, esophagitis, gastroenteritis, gastrointestinal disorder,
gastrointestinal hemorrhage, gum disorder, hepatitis, pancreatitis, parotid
gland enlargement, periodontitis, stomatitis, tongue discoloration, tooth
disorder.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Hemic
and Lymphatic:</span></i></b><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'> Aplastic anemia, macrocytic anemia,
megaloblastic anemia, microcytic anemia.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Metabolic
and Endocrine:</span></i></b><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'> Avitaminosis, bilirubinemia,
dehydration, hypercholesteremia, hypoglycemia, increased alkaline phosphatase,
increased lipase, increased serum creatinine, peripheral edema.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Muscular
Skeletal:</span></i></b><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;
font-family:"Times New Roman"'> Myalgia, myasthenia.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Nervous
System:</span></i></b><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;
font-family:"Times New Roman"'> Abnormal gait, ataxia, decreased libido,
decreased reflexes, dementia, dysesthesia, dyskinesia, emotional lability,
hostility, hypalgesia, hyperkinesia, incoordination, meningitis, neurologic
disorder, tremor, vertigo.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Respiratory
System:</span></i></b><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;
font-family:"Times New Roman"'> Apnea, bronchitis, lung disorder, lung edema,
pneumonia (including <i style='mso-bidi-font-style:normal'>Pneumocystis carinii</i>
pneumonia), rhinitis. <o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Skin
and Appendages:</span></i></b><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'> Angioedema, benign skin neoplasm,
eczema, herpes simplex, incomplete Stevens-Johnson syndrome, nail disorder,
pruritus, psoriasis, skin discoloration, skin disorder.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Special
Senses:</span></i></b><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;
font-family:"Times New Roman"'> Conjunctivitis, eye disorder, lacrimation
disorder, retinitis, taste perversion.<o:p></o:p></span></p>

<p class=MsoPlainText style='mso-list:skip'><b style='mso-bidi-font-weight:
normal'><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman";color:red'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></b></p>

<p class=MsoPlainText style='mso-outline-level:1;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman";color:black'>Other Adverse Events Observed
in Post-Marketing Use<o:p></o:p></span></b></p>

<p class=MsoPlainText style='mso-outline-level:1;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman";color:black'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></b></p>

<p class=MsoPlainText style='mso-outline-level:1;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";
color:black'>Cardiovascular System: </span></i></b><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman";color:black'>Cardiac
arrhythmias including atrial fibrillation, bradycardia, tachycardia, sick sinus
syndrome and EKG abnormalities.<o:p></o:p></span></p>

<p class=MsoPlainText style='mso-outline-level:1;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";
color:black'>Metabolic and Endocrine: </span></i></b><span style='font-size:
11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";color:black'>Electrolyte
imbalance including hypercalcemia or hypocalcemia, hyperkalemia and hypokalemia,
hyponatremia, hypothyroidism, and increased alkaline phosphatase.<o:p></o:p></span></p>

<p class=MsoPlainText style='mso-outline-level:1;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";
color:black'>Nervous System: </span></i></b><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman";color:black'>Changes in
mental status or mood including depression and suicide attempts, disturbances
in consciousness including lethargy, syncope, loss of consciousness or stupor,
seizures including grand mal convulsions and status epilepicus.<o:p></o:p></span></p>

<p class=MsoPlainText style='mso-outline-level:1;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";
color:black'>Skin and Appendages: </span></i></b><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman";color:black'>Erythema
multiforme.<o:p></o:p></span></p>

<p class=MsoPlainText style='mso-outline-level:1;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";
color:black'>Hemic and Lymphatic: </span></i></b><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman";color:black'>Decreased
white blood cell counts including neutropenia and febrile neutropenia, changes
in prothrombin time.<o:p></o:p></span></p>

<p class=MsoPlainText style='mso-outline-level:1;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";
color:black'>Respiratory System: </span></i></b><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman";color:black'>Pleural
effusion.</span><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;
font-family:"Times New Roman";color:red'><o:p></o:p></span></p>

<p class=MsoPlainText style='mso-outline-level:1;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";
color:red'><span style="mso-spacerun: yes"> </span><b style='mso-bidi-font-weight:
normal'><span style="mso-spacerun: yes"> </span><o:p></o:p></b></span></p>

<p class=MsoPlainText style='mso-outline-level:1;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'>Other Adverse Events in the Published
Literature or Reported from Other Sources<o:p></o:p></span></b></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>The following
additional events have been identified either in the published literature or
from spontaneous reports from other sources: acute renal failure, amenorrhea,
aphthous stomatitis, bile duct obstruction, carpal tunnel, chronic myelogenous
leukemia, diplopia, dysesthesia, dyspnea, enuresis, erythema nodosum,
erythroleukemia, foot drop, galactorrhea, gynecomastia, hangover effect,
hypomagnesemia, hypothyroidism, lymphedema, lymphopenia, metrorrhagia,
migraine, myxedema, nodular sclerosing Hodgkin’s disease, nystagmus, oliguria,
pancytopenia, petechiae, purpura, Raynaud’s syndrome, stomach ulcer, and
suicide attempt.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:6.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'>DRUG ABUSE AND DEPENDENCE</span></b><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><o:p></o:p></span></p>

<p class=MsoPlainText style='page-break-after:avoid;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Physical
and psychological dependence has not been reported in patients taking
thalidomide. However, as with other tranquilizers/hypnotics, thalidomide too
has been reported to create in patients habituation to its soporific effects.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:6.0pt;page-break-after:avoid;
mso-outline-level:1;mso-list:skip'><b style='mso-bidi-font-weight:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>OVERDOSAGE<o:p></o:p></span></b></p>

<p class=MsoPlainText style='page-break-after:avoid;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>There
have been three cases of overdose reported, all attempted suicides. There have
been no reported fatalities in doses of up to 14.4 grams, and all patients
recovered without reported sequelae.<o:p></o:p></span></p>

<p class=MsoPlainText style='mso-list:skip'><b style='mso-bidi-font-weight:
normal'><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></b></p>

<p class=MsoPlainText style='mso-outline-level:1;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'>DOSAGE AND ADMINISTRATION<o:p></o:p></span></b></p>

<p class=MsoPlainText style='margin-top:6.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'>THALOMID<sup>®</sup> (thalidomide) MUST
ONLY BE ADMINISTERED IN COMPLIANCE WITH ALL OF THE TERMS OUTLINED IN THE <i
style='mso-bidi-font-style:normal'>S.T.E.P.S.</i><sup><span style='color:red'> </span>®</sup>
PROGRAM. THALOMID<sup>®</sup> (thalidomide) MAY ONLY BE PRESCRIBED BY
PRESCRIBERS REGISTERED WITH THE <i style='mso-bidi-font-style:normal'>S.T.E.P.S.</i><sup><span
style='color:red'> </span>®</sup> PROGRAM AND MAY ONLY BE DISPENSED BY
PHARMACISTS REGISTERED WITH THE <i style='mso-bidi-font-style:normal'>S.T.E.P.S.</i><sup><span
style='color:red'> </span>® </sup>PROGRAM.<o:p></o:p></span></b></p>

<p class=MsoPlainText style='margin-top:4.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'>Drug prescribing to women of childbearing
potential should be contingent upon initial and continued confirmed negative
results of pregnancy testing.<span style="mso-spacerun: yes">  </span><o:p></o:p></span></b></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>For
an episode of cutaneous ENL, THALOMID<b style='mso-bidi-font-weight:normal'><sup>®</sup></b>
(thalidomide) dosing should be initiated at 100 to 300 mg/day, administered
once daily with water, preferably at bedtime and at least 1 hour after the
evening meal. Patients weighing less than 50 kilograms should be started at the
low end of the dose range.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>In
patients with a severe cutaneous ENL reaction, or in those who have previously
required higher doses to control the reaction, THALOMID<b style='mso-bidi-font-weight:
normal'><sup>®</sup></b> (thalidomide) dosing may be initiated at higher doses
up to 400 mg/day once daily at bedtime or in divided doses with water, at least
1 hour after meals. <o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>In
patients with moderate to severe neuritis associated with a severe ENL
reaction, corticosteroids may be started concomitantly with THALOMID<b
style='mso-bidi-font-weight:normal'><sup>®</sup></b> (thalidomide). Steroid
usage can be tapered and discontinued when the neuritis has ameliorated.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Dosing
with THALOMID<b style='mso-bidi-font-weight:normal'><sup>®</sup></b>
(thalidomide) should usually continue until signs and symptoms of active
reaction have subsided, usually a period of at least 2 weeks. Patients may then
be tapered off medication in 50 mg decrements every 2 to 4 weeks. <o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Patients
who have a documented history of requiring prolonged maintenance treatment to
prevent the recurrence of cutaneous ENL or who flare during tapering, should be
maintained on the minimum dose necessary to control the reaction. Tapering off
medication should be attempted every 3 to 6 months, in decrements of 50 mg
every 2 to 4 weeks.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:6.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'>HOW SUPPLIED<o:p></o:p></span></b></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'>(THIS PRODUCT IS ONLY SUPPLIED TO
PHARMACISTS REGISTERED WITH THE <i style='mso-bidi-font-style:normal'>S.T.E.P.S.</i><sup>
®</sup> PROGRAM - See BOXED WARNINGS.)<o:p></o:p></span></b></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>THALOMID<sup>®</sup>
(thalidomide) Capsules is supplied in the<span style='color:red'> </span>following
dosages:<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:3.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>50
mg capsules [white opaque], imprinted “Celgene / 50 mg” with a “Do Not Get
Pregnant” logo. <s><o:p></o:p></s></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Individual
blister packs of 28 capsules (NDC 59572-205-14).<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Boxes
of 280 containing 10 prescription packs of 28 capsules each (NDC 59572-205-94).<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:6.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>100
mg capsules [tan], imprinted “Celgene / 100 mg” with a “Do Not Get Pregnant”
logo.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Individual
blister packs of 28 capsules (NDC 59572-210-15).<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Boxes
of 140 containing 5 prescription packs of 28 capsules each (NDC 59572-210-95).<span
style='color:red'><o:p></o:p></span></span></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>200 mg capsules
[blue], imprinted “Celgene / 200 mg” with a “Do Not Get Pregnant” logo.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Individual
blister packs of 28 capsules (NDC 59572-220-16).<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Boxes
of 84 containing 3 prescription packs of 28 capsules each (NDC 59572-220-96).<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:6.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>STORAGE AND DISPENSING<o:p></o:p></span></b></p>

<p class=MsoPlainText style='margin-top:6.0pt;mso-outline-level:1;mso-list:
skip'><b style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>PHARMACISTS NOTE: <o:p></o:p></span></b></p>

<p class=MsoNormal style='margin-left:9.35pt;mso-list:skip'><b
style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
12.0pt'>BEFORE DISPENSING THALOMID<sup>®</sup> (thalidomide), YOU MUST ACTIVATE
THE AUTHORIZATION NUMBER ON EVERY PRESCRIPTION BY CALLING THE CELGENE CUSTOMER
CARE CENTER AT 1-888-4-CELGENE (1-888-423-5436) AND OBTAINING A CONFIRMATION
NUMBER. YOU MUST ALSO WRITE THE CONFIRMATION NUMBER ON THE PRESCRIPTION. YOU
SHOULD ACCEPT A PRESCRIPTION ONLY IF IT HAS BEEN ISSUED WITHIN THE PREVIOUS 7
DAYS (TELEPHONE PRESCRIPTIONS ARE NOT PERMITTED); DISPENSE NO MORE THAN A
4-WEEK (28-DAY) SUPPLY. A NEW PRESCRIPTION IS REQUIRED FOR FURTHER DISPENSING.<span
style='color:blue'> </span><span style="mso-spacerun: yes"> </span>DISPENSE
BLISTER PACKS INTACT (CAPSULES CANNOT BE REPACKAGED); DISPENSE SUBSEQUENT
PRESCRIPTIONS ONLY IF FEWER THAN 7 DAYS OF THERAPY REMAIN ON THE PREVIOUS
PRESCRIPTION; AND EDUCATE ALL STAFF PHARMACISTS ABOUT THE DISPENSING PROCEDURE
FOR THALOMID<sup>®</sup> (thalidomide).<o:p></o:p></span></b></p>

<p class=MsoPlainText style='margin-top:9.0pt;margin-right:0pt;margin-bottom:
3.0pt;margin-left:0pt;mso-list:skip'><span style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman"'>This drug must not be repackaged.<o:p></o:p></span></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Store at 25 º C (77º
F); excursions permitted to 15 – 30º C ( 59 -86º F). [See USP Controlled Room
Temperature].<span style='color:red'> </span>Protect from light.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-bottom:3.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Rx
only and only able to be prescribed and dispensed under the terms of the <i
style='mso-bidi-font-style:normal'>S.T.E.P.S</i><b style='mso-bidi-font-weight:
normal'>.<sup><span style='color:red'> </span>®</sup></b> Restricted
Distribution Program<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:6.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Manufactured
for Celgene Corporation<o:p></o:p></span></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>7 Powder Horn Drive<o:p></o:p></span></p>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Warren, New Jersey
07059<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:2.0pt;mso-list:skip'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>1-(888)
423-5436<o:p></o:p></span></p>

<p class=MsoPlainText style='mso-list:skip'><b style='mso-bidi-font-weight:
normal'><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman"'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></b></p>

<p class=MsoPlainText style='margin-bottom:6.0pt;mso-outline-level:1;
mso-list:skip'><b style='mso-bidi-font-weight:normal'><span style='font-size:
11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>Important
Information and Warnings for All Patients Taking THALOMID<sup>®</sup>
(thalidomide)<span style="mso-spacerun:
yes">                                                                   
</span><span style="mso-spacerun: yes">                </span><o:p></o:p></span></b></p>

<table border=0 cellspacing=0 cellpadding=0 style='margin-left:-13.2pt;
 border-collapse:collapse;mso-padding-alt:0pt 4.8pt 0pt 4.8pt'>
 <tr style='height:20.1pt'>
  <td width=684 valign=top style='width:513.0pt;border:solid windowtext .75pt;
  padding:0pt 4.8pt 0pt 4.8pt;height:20.1pt'>
  <p class=MsoNormal style='mso-list:skip'><b style='mso-bidi-font-weight:normal'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>WARNING: SEVERE,
  LIFE-THREATENING HUMAN BIRTH DEFECTS.<o:p></o:p></span></b></p>
  <p class=MsoNormal style='margin-top:3.0pt;mso-list:skip'><b
  style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt'>IF THALIDOMIDE IS TAKEN DURING PREGNANCY, IT CAN CAUSE SEVERE BIRTH
  DEFECTS OR DEATH TO AN UNBORN BABY. THALIDOMIDE SHOULD NEVER BE USED BY WOMEN
  WHO ARE PREGNANT OR WHO COULD BECOME PREGNANT WHILE TAKING THE DRUG. EVEN A
  SINGLE DOSE [1 CAPSULE (50 mg, 100 mg or 200 mg)] TAKEN BY A PREGNANT WOMAN
  CAN CAUSE SEVERE BIRTH DEFECTS.<o:p></o:p></span></b></p>
  </td>
 </tr>
</table>

<p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'><span
style="mso-spacerun: yes">                                                    
</span><b style='mso-bidi-font-weight:normal'><u><o:p></o:p></u></b></span></p>

<table border=1 cellspacing=0 cellpadding=0 style='margin-left:-12.6pt;
 border-collapse:collapse;border:none;mso-border-alt:solid windowtext .75pt;
 mso-padding-alt:0pt 5.4pt 0pt 5.4pt'>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border:solid windowtext .75pt;
  border-bottom:none;padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoPlainText style='mso-list:skip'><b style='mso-bidi-font-weight:
  normal'><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:
  "Times New Roman";color:black'>All Patients<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border-top:none;border-left:
  solid windowtext .75pt;border-bottom:none;border-right:solid windowtext .75pt;
  padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoPlainText style='margin-top:0pt;margin-right:0pt;margin-bottom:
  2.0pt;margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo3;
  tab-stops:18.0pt'><![if !supportLists]><span style='font-size:9.0pt;
  mso-bidi-font-size:10.0pt;font-family:Symbol;color:black'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman";color:black'>The patient understands
  that severe birth defects can occur with the use of THALOMID<sup>®</sup>
  (thalidomide).<o:p></o:p></span></p>
  </td>
 </tr>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border-top:none;border-left:
  solid windowtext .75pt;border-bottom:none;border-right:solid windowtext .75pt;
  padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoPlainText style='margin-top:0pt;margin-right:0pt;margin-bottom:
  2.0pt;margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo3;
  tab-stops:18.0pt'><![if !supportLists]><span style='font-size:9.0pt;
  mso-bidi-font-size:10.0pt;font-family:Symbol;color:black'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman";color:black'>The patient has been warned
  by his/her doctor that an unborn baby will almost certainly have </span><span
  style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>severe<span
  style='color:red'> </span><span style='color:black'>birth defects and can
  even die, if a woman is pregnant or becomes pregnant while taking THALOMID<sup>®</sup>
  (thalidomide).<o:p></o:p></span></span></p>
  </td>
 </tr>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border-top:none;border-left:
  solid windowtext .75pt;border-bottom:none;border-right:solid windowtext .75pt;
  padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoNormal style='margin-top:0pt;margin-right:0pt;margin-bottom:2.0pt;
  margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo3;tab-stops:
  18.0pt'><![if !supportLists]><span style='font-size:9.0pt;mso-bidi-font-size:
  12.0pt;font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt;color:black'>THALOMID<sup>®</sup> (thalidomide) will be prescribed
  ONLY for the patient and must NOT be shared with ANYONE, even someone who has
  similar symptoms. <o:p></o:p></span></p>
  </td>
 </tr>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border-top:none;border-left:
  solid windowtext .75pt;border-bottom:none;border-right:solid windowtext .75pt;
  padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoNormal style='margin-left:18.0pt;text-indent:-18.0pt;mso-list:
  l0 level1 lfo3;tab-stops:18.0pt'><![if !supportLists]><span style='font-size:
  9.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol;color:black'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt;color:black'>THALOMID<sup>®</sup> (thalidomide) must be kept out of
  the reach of children and should NEVER be<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:0pt;margin-right:0pt;margin-bottom:2.0pt;
  margin-left:18.0pt'><span style='font-size:11.0pt;mso-bidi-font-size:12.0pt;
  color:black'><span style="mso-spacerun: yes">      </span>given to women who
  are able to have children.<o:p></o:p></span></p>
  </td>
 </tr>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border-top:none;border-left:
  solid windowtext .75pt;border-bottom:none;border-right:solid windowtext .75pt;
  padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoPlainText style='margin-top:0pt;margin-right:0pt;margin-bottom:
  2.0pt;margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo3;
  tab-stops:18.0pt'><![if !supportLists]><span style='font-size:9.0pt;
  mso-bidi-font-size:10.0pt;font-family:Symbol;color:black'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman";color:black'>The patient cannot donate
  blood while taking THALOMID<sup>®</sup> (thalidomide).<o:p></o:p></span></p>
  </td>
 </tr>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border-top:none;border-left:
  solid windowtext .75pt;border-bottom:none;border-right:solid windowtext .75pt;
  padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoNormal style='margin-top:0pt;margin-right:0pt;margin-bottom:2.0pt;
  margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo3;tab-stops:
  18.0pt'><![if !supportLists]><span style='font-size:9.0pt;mso-bidi-font-size:
  12.0pt;font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt;color:black'>The patient has read the THALOMID<sup>®</sup>
  (thalidomide) patient brochure and/or viewed the videotape, “Important
  Information for Men and Women Taking THALOMID<sup>®</sup> (thalidomide)” and
  understands the contents, including other possible health problems from
  THALOMID<sup>®</sup> (thalidomide), “side effects.”<o:p></o:p></span></p>
  </td>
 </tr>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border-top:none;border-left:
  solid windowtext .75pt;border-bottom:none;border-right:solid windowtext .75pt;
  padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoPlainText style='margin-top:0pt;margin-right:0pt;margin-bottom:
  2.0pt;margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo3;
  tab-stops:18.0pt'><![if !supportLists]><span style='font-size:9.0pt;
  mso-bidi-font-size:10.0pt;font-family:Symbol;color:black'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman";color:black'>The patient’s doctor has
  answered any questions the patient has asked.<o:p></o:p></span></p>
  </td>
 </tr>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border:solid windowtext .75pt;
  border-top:none;padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoNormal style='margin-top:0pt;margin-right:0pt;margin-bottom:2.0pt;
  margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo3;tab-stops:
  18.0pt'><![if !supportLists]><span style='font-size:9.0pt;mso-bidi-font-size:
  12.0pt;font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt;color:black'>The patient must participate in a telephone survey and
  patient registry, while taking THALOMID<sup>®</sup> (thalidomide).<o:p></o:p></span></p>
  </td>
 </tr>
</table>

<h5><span style='color:black;font-weight:normal'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></h5>

<table border=1 cellspacing=0 cellpadding=0 style='margin-left:-12.6pt;
 border-collapse:collapse;border:none;mso-border-alt:solid windowtext .5pt;
 mso-padding-alt:0pt 5.4pt 0pt 5.4pt'>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border:solid windowtext .5pt;
  border-bottom:none;padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoPlainText style='mso-list:skip'><b style='mso-bidi-font-weight:
  normal'><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:
  "Times New Roman";color:black'>Female Patients of Childbearing Potential<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border-top:none;border-left:
  solid windowtext .5pt;border-bottom:none;border-right:solid windowtext .5pt;
  padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoNormal style='margin-top:0pt;margin-right:0pt;margin-bottom:2.0pt;
  margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo3;tab-stops:
  18.0pt'><![if !supportLists]><span style='font-size:9.0pt;mso-bidi-font-size:
  12.0pt;font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt;color:black'>The patient must not take THALOMID<sup>®</sup>
  (thalidomide) if she is pregnant, breast-feeding a baby, or able to get
  pregnant and not using the required two methods of birth control.<b
  style='mso-bidi-font-weight:normal'><o:p></o:p></b></span></p>
  </td>
 </tr>
 <tr style='height:4.0pt'>
  <td width=684 valign=top style='width:513.0pt;border-top:none;border-left:
  solid windowtext .5pt;border-bottom:none;border-right:solid windowtext .5pt;
  padding:0pt 5.4pt 0pt 5.4pt;height:4.0pt'>
  <p class=MsoNormal style='margin-top:0pt;margin-right:0pt;margin-bottom:2.0pt;
  margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo3;tab-stops:
  18.0pt'><![if !supportLists]><span style='font-size:9.0pt;mso-bidi-font-size:
  12.0pt;font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt;color:black'>The patient confirms that she is not now pregnant, nor
  will she try to become pregnant during THALOMID<sup>®</sup> (thalidomide)
  therapy and for at least 4 weeks after she has completely finished taking
  THALOMID<sup>®</sup> (thalidomide). <b style='mso-bidi-font-weight:normal'><o:p></o:p></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border-top:none;border-left:
  solid windowtext .5pt;border-bottom:none;border-right:solid windowtext .5pt;
  padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoNormal style='margin-left:18.0pt;text-indent:-18.0pt;mso-list:
  l0 level1 lfo3;tab-stops:18.0pt'><![if !supportLists]><span style='font-size:
  9.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol;color:black'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt;color:black'>If the patient is able to become pregnant, she must use
  at least one highly effective method and one additional effective method of
  birth control (contraception) AT THE SAME TIME:<o:p></o:p></span></p>
  <h6 style='margin-left:0pt'><span style='color:black'><span
  style="mso-spacerun: yes">      </span>At least one highly effective method<span
  style='mso-tab-count:1'>            </span><span style="mso-spacerun:
  yes">        </span><u>AND</u> <span style='mso-tab-count:1'>       </span><span
  style="mso-spacerun: yes">  </span>One additional effective method<o:p></o:p></span></h6>
  <p class=MsoNormal style='text-indent:18.0pt;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt;color:black'><span
  style="mso-spacerun: yes">      </span>IUD<span style='mso-tab-count:7'>                                                                             </span><span
  style="mso-spacerun: yes">  </span>Latex condom<o:p></o:p></span></p>
  <p class=MsoNormal style='text-indent:22.5pt;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt;color:black'><span
  style="mso-spacerun: yes">      </span>Hormonal (birth control pills,
  injections, or implants) <span style='mso-tab-count:1'>       </span><span
  style="mso-spacerun: yes">  </span>Diaphragm<o:p></o:p></span></p>
  <p class=MsoNormal style='mso-list:skip;tab-stops:36.0pt'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt;color:black'><span
  style="mso-spacerun: yes">            </span>Tubal ligation<span
  style='mso-tab-count:6'>                                                                 </span><span
  style="mso-spacerun: yes">  </span>Cervical cap<o:p></o:p></span></p>
  <p class=MsoNormal style='margin-bottom:2.0pt;mso-list:skip;tab-stops:36.0pt'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt;color:black'><span
  style="mso-spacerun: yes">              </span>Partner’s vasectomy<b
  style='mso-bidi-font-weight:normal'><o:p></o:p></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border-top:none;border-left:
  solid windowtext .5pt;border-bottom:none;border-right:solid windowtext .5pt;
  padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoNormal style='margin-top:0pt;margin-right:0pt;margin-bottom:2.0pt;
  margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo3;tab-stops:
  18.0pt 36.0pt'><![if !supportLists]><span style='font-size:9.0pt;mso-bidi-font-size:
  12.0pt;font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt;color:black'>These birth control methods must be used for at least 4 weeks
  before </span><span style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>beginning
  <span style='color:black'>THALOMID<sup>®</sup> (thalidomide) therapy, during
  THALOMID<sup>®</sup> (thalidomide) therapy, and for 4 weeks </span>following
  discontinuation of<span style='color:black'> THALOMID<sup>®</sup>
  (thalidomide) therapy.<b style='mso-bidi-font-weight:normal'><o:p></o:p></b></span></span></p>
  </td>
 </tr>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border-top:none;border-left:
  solid windowtext .5pt;border-bottom:none;border-right:solid windowtext .5pt;
  padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoNormal style='margin-top:0pt;margin-right:0pt;margin-bottom:2.0pt;
  margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo3;tab-stops:
  18.0pt 292.5pt'><![if !supportLists]><span style='font-size:9.0pt;mso-bidi-font-size:
  12.0pt;font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt;color:black'>The patient must use these birth control methods unless
  she <u>completely abstains from heterosexual sexual contact</u>.<b
  style='mso-bidi-font-weight:normal'><o:p></o:p></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border-top:none;border-left:
  solid windowtext .5pt;border-bottom:none;border-right:solid windowtext .5pt;
  padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoNormal style='margin-top:0pt;margin-right:0pt;margin-bottom:2.0pt;
  margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo3;tab-stops:
  18.0pt'><![if !supportLists]><span style='font-size:9.0pt;mso-bidi-font-size:
  12.0pt;font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt;color:black'>If a hormonal method (birth control pills, injections, or
  implants) or IUD is not medically possible for the patient, she may use
  another highly effective method or two barrier methods AT THE SAME TIME.<b
  style='mso-bidi-font-weight:normal'><o:p></o:p></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border-top:none;border-left:
  solid windowtext .5pt;border-bottom:none;border-right:solid windowtext .5pt;
  padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoNormal style='margin-top:0pt;margin-right:0pt;margin-bottom:2.0pt;
  margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo3;tab-stops:
  18.0pt'><![if !supportLists]><span style='font-size:9.0pt;mso-bidi-font-size:
  12.0pt;font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt;color:black'>The patient must have a pregnancy test done by her doctor
  within the 24 hours prior to starting THALOMID<sup>®</sup> (thalidomide)
  therapy, then <u>every week</u> during the first 4 weeks of THALOMID<sup>®</sup>(thalidomide)
  therapy. <b style='mso-bidi-font-weight:normal'><o:p></o:p></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border-top:none;border-left:
  solid windowtext .5pt;border-bottom:none;border-right:solid windowtext .5pt;
  padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoNormal style='margin-top:0pt;margin-right:0pt;margin-bottom:2.0pt;
  margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo3;tab-stops:
  18.0pt'><![if !supportLists]><span style='font-size:9.0pt;mso-bidi-font-size:
  12.0pt;font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt;color:black'>Thereafter, the patient must have a pregnancy test <u>every
  4 weeks</u> if she has regular menstrual cycles, or <u>every 2 weeks</u> if
  her cycles are irregular while she is taking THALOMID<sup>®</sup>
  (thalidomide).<b style='mso-bidi-font-weight:normal'><o:p></o:p></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border-top:none;border-left:
  solid windowtext .5pt;border-bottom:none;border-right:solid windowtext .5pt;
  padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoNormal style='margin-left:18.0pt;text-indent:-18.0pt;mso-list:
  l0 level1 lfo3;tab-stops:18.0pt'><![if !supportLists]><span style='font-size:
  9.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol;color:black'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt;color:black'>The patient must immediately stop taking THALOMID<sup>®</sup>
  (thalidomide) and inform her doctor:<o:p></o:p></span></p>
  <p class=MsoNormal><span style='font-size:11.0pt;mso-bidi-font-size:12.0pt;
  color:black'><span style="mso-spacerun: yes">                        
  </span>If she becomes pregnant while taking the drug<o:p></o:p></span></p>
  <p class=MsoNormal style='mso-list:skip'><span style='font-size:11.0pt;
  mso-bidi-font-size:12.0pt;color:black'><span style="mso-spacerun:
  yes">                         </span>If she misses her menstrual period, or
  experiences unusual menstrual bleeding<o:p></o:p></span></p>
  <p class=MsoNormal style='mso-list:skip'><span style='font-size:11.0pt;
  mso-bidi-font-size:12.0pt;color:black'><span style="mso-spacerun:
  yes">                         </span>If she stops using birth control<o:p></o:p></span></p>
  <p class=MsoNormal style='mso-list:skip'><span style='font-size:11.0pt;
  mso-bidi-font-size:12.0pt;color:black'><span style="mso-spacerun:
  yes">                         </span>If she thinks FOR ANY REASON that she
  may be pregnant<o:p></o:p></span></p>
  <div style='border:none;border-bottom:solid windowtext .5pt;padding:0pt 0pt 1.0pt 0pt'>
  <p class=MsoPlainText style='mso-list:skip;border:none;mso-border-bottom-alt:
  solid windowtext .5pt;padding:0pt;mso-padding-alt:0pt 0pt 1.0pt 0pt'><span
  style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";
  color:black'><span style="mso-spacerun: yes">             </span>The patient
  understands that if her doctor is not available, she can call 1-888-668-2528
  for<span style="mso-spacerun: yes">  </span><o:p></o:p></span></p>
  </div>
  <div style='border:none;border-bottom:solid windowtext .5pt;padding:0pt 0pt 1.0pt 0pt'>
  <p class=MsoPlainText style='margin-top:0pt;margin-right:0pt;margin-bottom:
  2.0pt;margin-left:18.0pt;text-indent:-18.0pt;mso-list:skip;border:none;
  mso-border-bottom-alt:solid windowtext .5pt;padding:0pt;mso-padding-alt:0pt 0pt 1.0pt 0pt'><span
  style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";
  color:black'><span style="mso-spacerun: yes">             </span>information
  on emergency contraception</span><span style='font-size:11.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman";color:red'>.<b style='mso-bidi-font-weight:
  normal'><o:p></o:p></b></span></p>
  </div>
  </td>
 </tr>
</table>

<p class=MsoPlainText style='mso-list:skip'><b style='mso-bidi-font-weight:
normal'><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman";color:black'><span style="mso-spacerun:
yes">                                                                </span><u><o:p></o:p></u></span></b></p>

<table border=1 cellspacing=0 cellpadding=0 style='margin-left:-12.6pt;
 border-collapse:collapse;border:none;mso-border-alt:solid windowtext .75pt;
 mso-padding-alt:0pt 5.4pt 0pt 5.4pt'>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border:solid windowtext .75pt;
  padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoHeading7 style='mso-list:skip'><span style='font-family:"Times New Roman";
  color:black'>Female Patients Not of Childbearing Potential<o:p></o:p></span></p>
  <p class=MsoPlainText style='margin-top:0pt;margin-right:0pt;margin-bottom:
  2.0pt;margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo3;
  tab-stops:18.0pt'><![if !supportLists]><span style='font-size:9.0pt;
  mso-bidi-font-size:10.0pt;font-family:Symbol;color:black'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman";color:black'>The patient certifies that
  she is not now pregnant, nor of childbearing potential as she has been
  postmenopausal for at least 24 months (been through the change of life); or
  she has had a hysterectomy.<o:p></o:p></span></p>
  <p class=MsoBodyText2 style='margin-top:0pt;margin-right:0pt;margin-bottom:
  2.0pt;margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo3;
  tab-stops:18.0pt'><![if !supportLists]><span style='font-size:9.0pt;
  mso-bidi-font-size:10.0pt;font-family:Symbol;color:black'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-family:"Times New Roman";
  color:black'>The patient or guardian certifies that a prepubertal female
  child is not now pregnant, nor is of childbearing potential as menstruation
  has not yet begun, and/or the child will not be engaging in heterosexual
  sexual contact for at least 4 weeks before THALOMID<sup>®</sup> (thalidomide)
  therapy, during THALOMID<sup>® </sup>(thalidomide) therapy, </span><span
  style='font-family:"Times New Roman"'>and <span style='color:black'>for at
  least 4 weeks after stopping therapy.<b style='mso-bidi-font-weight:normal'><o:p></o:p></b></span></span></p>
  </td>
 </tr>
</table>

<p class=MsoPlainText><b style='mso-bidi-font-weight:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";
color:black'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></b></p>

<table border=1 cellspacing=0 cellpadding=0 style='margin-left:-12.6pt;
 border-collapse:collapse;border:none;mso-border-alt:solid windowtext .75pt;
 mso-padding-alt:0pt 5.4pt 0pt 5.4pt'>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border:solid windowtext .75pt;
  border-bottom:none;padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoPlainText style='mso-list:skip'><b style='mso-bidi-font-weight:
  normal'><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:
  "Times New Roman";color:black'>Male Patients<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border-top:none;border-left:
  solid windowtext .75pt;border-bottom:none;border-right:solid windowtext .75pt;
  padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoNormal style='margin-top:0pt;margin-right:0pt;margin-bottom:2.0pt;
  margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo3;tab-stops:
  18.0pt'><![if !supportLists]><span style='font-size:9.0pt;mso-bidi-font-size:
  12.0pt;font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt;color:black'>The patient has been told by his doctor that he must
  NEVER have unprotected sexual contact with a woman who can become pregnant.<b
  style='mso-bidi-font-weight:normal'><o:p></o:p></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border-top:none;border-left:
  solid windowtext .75pt;border-bottom:none;border-right:solid windowtext .75pt;
  padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoNormal style='margin-top:0pt;margin-right:0pt;margin-bottom:2.0pt;
  margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo3;tab-stops:
  18.0pt'><![if !supportLists]><span style='font-size:9.0pt;mso-bidi-font-size:
  12.0pt;font-family:Symbol;color:black'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt;color:black'>Because THALOMID<sup>®</sup> (thalidomide) is present in
  semen, his doctor has explained that he must either completely abstain from
  sexual contact with women who are pregnant or able to become pregnant, or he
  must use a latex condom EVERY TIME he engages in any sexual contact with
  women who are pregnant or may become pregnant while he is taking THALOMID<sup>®</sup>
  (thalidomide) and for 4 weeks after he stops taking the drug, even if he has
  had a successful vasectomy. <b style='mso-bidi-font-weight:normal'><o:p></o:p></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border-top:none;border-left:
  solid windowtext .75pt;border-bottom:none;border-right:solid windowtext .75pt;
  padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoNormal style='margin-left:18.0pt;text-indent:-18.0pt;mso-list:
  l0 level1 lfo3;tab-stops:18.0pt'><![if !supportLists]><span style='font-size:
  9.0pt;mso-bidi-font-size:12.0pt;font-family:Symbol;color:black'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  12.0pt;color:black'>The patient must inform his doctor:<o:p></o:p></span></p>
  <p class=MsoNormal><span style='font-size:11.0pt;mso-bidi-font-size:12.0pt;
  color:black'><span style="mso-spacerun: yes">                       
  </span>If he has had unprotected sexual contact with a woman who can become
  pregnant<o:p></o:p></span></p>
  <p class=MsoNormal style='mso-list:skip'><span style='font-size:11.0pt;
  mso-bidi-font-size:12.0pt;color:black'><span style="mso-spacerun:
  yes">                        </span>If he thinks FOR ANY REASON, that his
  sexual partner may be pregnant</span><span style='font-size:11.0pt;
  mso-bidi-font-size:12.0pt;color:red'>.<o:p></o:p></span></p>
  <p class=MsoPlainText style='mso-list:skip'><span style='font-size:11.0pt;
  mso-bidi-font-size:10.0pt;font-family:"Times New Roman";color:black'><span
  style="mso-spacerun: yes">             </span>The patient understands that if
  his doctor is not available, he can call 1-888-668-2528 for<span
  style="mso-spacerun: yes">  </span><o:p></o:p></span></p>
  <p class=MsoPlainText style='margin-top:0pt;margin-right:0pt;margin-bottom:
  2.0pt;margin-left:18.0pt;text-indent:-18.0pt;mso-list:skip'><span
  style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";
  color:black'><span style="mso-spacerun: yes">             </span>information
  on emergency contraception.<b style='mso-bidi-font-weight:normal'><o:p></o:p></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border:solid windowtext .75pt;
  border-top:none;padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoPlainText style='margin-top:0pt;margin-right:0pt;margin-bottom:
  2.0pt;margin-left:18.0pt;text-indent:-18.0pt;mso-list:l0 level1 lfo3;
  tab-stops:18.0pt'><![if !supportLists]><span style='font-size:9.0pt;
  mso-bidi-font-size:10.0pt;font-family:Symbol;color:black'>·<span
  style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  </span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:
  10.0pt;font-family:"Times New Roman";color:black'>The patient cannot donate
  semen </span><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;
  font-family:"Times New Roman"'>or sperm<span style='color:red'> </span><span
  style='color:black'>while taking THALOMID<sup>®</sup> (thalidomide).<b
  style='mso-bidi-font-weight:normal'><o:p></o:p></b></span></span></p>
  </td>
 </tr>
</table>

<p class=MsoPlainText><b style='mso-bidi-font-weight:normal'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";
color:black'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></b></p>

<table border=1 cellspacing=0 cellpadding=0 style='margin-left:-12.6pt;
 border-collapse:collapse;border:none;mso-border-alt:solid windowtext .75pt;
 mso-padding-alt:0pt 5.4pt 0pt 5.4pt'>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border:solid windowtext .75pt;
  border-bottom:none;padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoPlainText><b style='mso-bidi-font-weight:normal'><span
  style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";
  color:black'>Authorization:<o:p></o:p></span></b></p>
  </td>
 </tr>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border-top:none;border-left:
  solid windowtext .75pt;border-bottom:none;border-right:solid windowtext .75pt;
  padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoNormal style='tab-stops:4.5pt 13.5pt'><span style='font-size:
  11.0pt;mso-bidi-font-size:12.0pt;color:black'>This information has been read
  aloud to me in the language of my choice. I understand that if I do not
  follow all of my doctor’s instructions, I will not be able to receive
  THALOMID<sup>® </sup>(thalidomide). <o:p></o:p></span></p>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:0pt;margin-bottom:
  3.0pt;margin-left:0pt'><span style='font-size:11.0pt;mso-bidi-font-size:12.0pt;
  color:black'>I now authorize my doctor to begin my treatment with THALOMID<sup>®</sup>
  (thalidomide).<b style='mso-bidi-font-weight:normal'><o:p></o:p></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border-top:none;border-left:
  solid windowtext .75pt;border-bottom:none;border-right:solid windowtext .75pt;
  padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoNormal style='margin-bottom:3.0pt'><span style='font-size:11.0pt;
  mso-bidi-font-size:12.0pt;color:black'>Patient
  Signature______________________________________Date____________________<b
  style='mso-bidi-font-weight:normal'><o:p></o:p></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border-top:none;border-left:
  solid windowtext .75pt;border-bottom:none;border-right:solid windowtext .75pt;
  padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoNormal><span style='font-size:11.0pt;mso-bidi-font-size:12.0pt;
  color:black'>I have fully explained to the patient the nature, purpose, and
  risks of the treatment described above, especially the risks to women of
  childbearing potential. I have asked the patient if he/she has any questions
  regarding his/her treatment with THALOMID<sup>®</sup> (thalidomide) and have
  answered those questions to the best of my ability. I will comply with all of
  my obligations and responsibilities as a prescriber registered under the <i
  style='mso-bidi-font-style:normal'>S.T.E.P.S.</i></span><sup><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt;color:red'> </span></sup><sup><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt'>®<span style='color:black'>
  </span></span></sup><span style='font-size:11.0pt;mso-bidi-font-size:12.0pt;
  color:black'>restricted distribution program.<b style='mso-bidi-font-weight:
  normal'><o:p></o:p></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border-top:none;border-left:
  solid windowtext .75pt;border-bottom:none;border-right:solid windowtext .75pt;
  padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoNormal style='margin-bottom:3.0pt;tab-stops:4.5pt'><span
  style='font-size:11.0pt;mso-bidi-font-size:12.0pt;color:black'>Prescriber
  Name (please type): ___________________________________________________<b
  style='mso-bidi-font-weight:normal'><o:p></o:p></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border-top:none;border-left:
  solid windowtext .75pt;border-bottom:none;border-right:solid windowtext .75pt;
  padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoNormal style='margin-top:3.0pt'><span style='font-size:11.0pt;
  mso-bidi-font-size:12.0pt;color:black'>DEA Number:__________________ Social
  Security Number if PA or NP:<span style="mso-spacerun: yes"> 
  </span>_________________<b style='mso-bidi-font-weight:normal'><o:p></o:p></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border-top:none;border-left:
  solid windowtext .75pt;border-bottom:none;border-right:solid windowtext .75pt;
  padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoPlainText style='margin-top:3.0pt'><span style='font-size:11.0pt;
  mso-bidi-font-size:10.0pt;font-family:"Times New Roman";color:black'>Street
  Address:<span style="mso-spacerun: yes"> 
  </span>________________________________________________________________<b
  style='mso-bidi-font-weight:normal'><o:p></o:p></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border-top:none;border-left:
  solid windowtext .75pt;border-bottom:none;border-right:solid windowtext .75pt;
  padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoPlainText style='margin-top:3.0pt'><span style='font-size:11.0pt;
  mso-bidi-font-size:10.0pt;font-family:"Times New Roman";color:black'>City:
  ____________________________ State: _____________________ Zip: ______________<u>
  </u><b style='mso-bidi-font-weight:normal'><o:p></o:p></b></span></p>
  </td>
 </tr>
 <tr>
  <td width=684 valign=top style='width:513.0pt;border:solid windowtext .75pt;
  border-top:none;padding:0pt 5.4pt 0pt 5.4pt'>
  <p class=MsoPlainText style='margin-top:3.0pt;margin-right:0pt;margin-bottom:
  3.0pt;margin-left:0pt'><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;
  font-family:"Times New Roman";color:black'>Prescriber Signature
  ____________________________________________________________<b
  style='mso-bidi-font-weight:normal'><u><o:p></o:p></u></b></span></p>
  </td>
 </tr>
</table>

<p class=MsoPlainText style='margin-top:6.0pt'><b style='mso-bidi-font-weight:
normal'><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman";color:black'><span style="mso-spacerun: yes">  </span><o:p></o:p></span></b></p>

<p class=MsoPlainText style='margin-top:6.0pt'><b style='mso-bidi-font-weight:
normal'><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman";color:black'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></b></p>

<p class=MsoPlainText style='margin-top:6.0pt'><b style='mso-bidi-font-weight:
normal'><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman";color:black'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></b></p>

<p class=MsoPlainText style='margin-top:6.0pt'><b style='mso-bidi-font-weight:
normal'><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman";color:black'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></b></p>

<p class=MsoPlainText style='margin-top:6.0pt'><b style='mso-bidi-font-weight:
normal'><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman";color:black'><span style="mso-spacerun: yes"> 
</span>REFERENCES<span style="mso-spacerun:
yes">                                                               </span><u><o:p></o:p></u></span></b></p>

<p class=MsoPlainText style='margin-left:36.0pt;text-indent:-36.0pt'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";
color:black'><span style="mso-spacerun: yes">  </span>1.<span style='mso-tab-count:
1'>       </span>Manson JM. 1986. Teratogenicity. Cassarett and Doull’s
Toxicology: The Basic Science of Poisons. Third Edition. Pages 195-220. New
York: MacMillan Publishing Co.<o:p></o:p></span></p>

<p class=MsoPlainText><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;
font-family:"Times New Roman";color:black'><span style="mso-spacerun: yes"> 
</span>2.<span style='mso-tab-count:1'>       </span>Smithels RW and Newman CG.
1992. J. Med. Genet. </span><span lang=FR style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman";color:black;mso-ansi-language:FR'>29(10):716-723.<o:p></o:p></span></p>

<p class=MsoPlainText><span lang=FR style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman";color:black;mso-ansi-language:FR'><span
style="mso-spacerun: yes">  </span>3.<span style='mso-tab-count:1'>       </span>Sampaio
EP, Kaplan G, Miranda A, <i style='mso-bidi-font-style:normal'>et al</i>. 1993.
J. Infect. Dis. 168(2):408-414.<o:p></o:p></span></p>

<p class=MsoPlainText><span lang=FR style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman";color:black;mso-ansi-language:FR'><span
style="mso-spacerun: yes">  </span>4.<span style='mso-tab-count:1'>       </span>Sarno
EN, Grau GE, Vieira LM, <i style='mso-bidi-font-style:normal'>et al</i>. 1991.
Clin. Exp. Immunol. 84:103-108.<o:p></o:p></span></p>

<p class=MsoPlainText><span lang=FR style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman";color:black;mso-ansi-language:FR'><span
style="mso-spacerun: yes">  </span>5.<span style='mso-tab-count:1'>       </span>Sampaio
EP, Moreira AL, Sarno EN, <i style='mso-bidi-font-style:normal'>et al</i>.
1992. J. Exp. Med. 175:1729-1737.<o:p></o:p></span></p>

<p class=MsoPlainText><span lang=FR style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman";color:black;mso-ansi-language:FR'><span
style="mso-spacerun: yes">  </span>6.<span style='mso-tab-count:1'>       </span>Nogueira
AC, Neubert R, Helge H, <i style='mso-bidi-font-style:normal'>et al</i>. 1994. </span><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";
color:black'>Life Sciences. 55(2):77-92.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-left:36.0pt;text-indent:-36.0pt'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";
color:black'><span style="mso-spacerun: yes">  </span>7.<span style='mso-tab-count:
1'>       </span>Jacobson JM, Greenspan JS, Spritzler J, <i style='mso-bidi-font-style:
normal'>et al</i>. 1997. New Eng. J. Med. 336(21):1487-1493<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-left:36.0pt;text-indent:-30.0pt;mso-list:
l1 level1 lfo5;tab-stops:36.0pt'><![if !supportLists]><span style='font-size:
11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";color:black'>8.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><![endif]><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;
font-family:"Times New Roman";color:black'>Eriksson T, Björkman S, Roth B, <i
style='mso-bidi-font-style:normal'>et al</i>. 1998. Chirality. 10(3): 223-228. <o:p></o:p></span></p>

<p class=MsoPlainText style='margin-left:6.0pt'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman";color:black'>9.<span
style='mso-tab-count:1'>       </span>Schumaker H, Smith RL, and Williams RT.
1965. </span><span lang=FR style='font-size:11.0pt;mso-bidi-font-size:10.0pt;
font-family:"Times New Roman";color:black;mso-ansi-language:FR'>Br. J.
Pharmacol. 25:324-337.<o:p></o:p></span></p>

<p class=MsoPlainText><span lang=FR style='font-size:11.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman";color:black;mso-ansi-language:FR'>10.<span
style='mso-tab-count:1'>        </span>Iyer CGS, Languillon J, Ramanujam K, <i
style='mso-bidi-font-style:normal'>et al</i>. 1971. </span><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";
color:black'>Bull. WHO. 45:719-732.<o:p></o:p></span></p>

<p class=MsoPlainText><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;
font-family:"Times New Roman";color:black'>11.<span style='mso-tab-count:1'>        </span>Sheskin
J and Convit J. 1969. Intl. J. Leprosy. 37:135-146.<o:p></o:p></span></p>

<p class=MsoPlainText><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;
font-family:"Times New Roman";color:black'>12.<span style='mso-tab-count:1'>        </span>Waters
MFR. 1971. Lepr. Rev. 42:26-42.<o:p></o:p></span></p>

<p class=MsoPlainText><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;
font-family:"Times New Roman"'>13. <span style='mso-tab-count:1'>       </span>Unpublished
data, on file at Celgene.<o:p></o:p></span></p>

<p class=MsoPlainText style='margin-top:6.0pt;margin-right:0pt;margin-bottom:
0pt;margin-left:36.0pt;margin-bottom:.0001pt;text-indent:-36.0pt'><span
style='font-size:11.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman"'>S.T.E.P.S.®<span
style="mso-spacerun: yes">  </span>is a registered trademark of Celgene
Corporation. <o:p></o:p></span></p>

<p class=MsoPlainText><span style='font-size:11.0pt;mso-bidi-font-size:10.0pt;
font-family:"Times New Roman"'>U.S. Pat. Nos. 6,045,501 &amp; 6,315,720.<span
style='color:red'><span style="mso-spacerun: yes">  </span><o:p></o:p></span></span></p>

<p class=MsoPlainText style='mso-outline-level:1'><span style='font-size:11.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman";color:black'>THALPI.008<span
style="mso-spacerun: yes">  </span>10/03 CG<o:p></o:p></span></p>

<p class=MsoNormal><span style='font-size:11.0pt;mso-bidi-font-size:12.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

<p class=MsoNormal><span style='font-size:11.0pt;mso-bidi-font-size:12.0pt'><![if !supportEmptyParas]>&nbsp;<![endif]><o:p></o:p></span></p>

</div>

</body>

</html>
